EP1362046A1 - Derives de pyrimidinone substitues en tant que ligands de recepteurs de l'integrine - Google Patents

Derives de pyrimidinone substitues en tant que ligands de recepteurs de l'integrine

Info

Publication number
EP1362046A1
EP1362046A1 EP02716798A EP02716798A EP1362046A1 EP 1362046 A1 EP1362046 A1 EP 1362046A1 EP 02716798 A EP02716798 A EP 02716798A EP 02716798 A EP02716798 A EP 02716798A EP 1362046 A1 EP1362046 A1 EP 1362046A1
Authority
EP
European Patent Office
Prior art keywords
optionally substituted
radical
alkylene
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02716798A
Other languages
German (de)
English (en)
Inventor
Herv Geneste
Andreas Kling
Johann-Christian Zechel
Arnulf Lauterbach
Werner Seitz
Claudia Isabella Graef
Thomas Subkowski
Wilfried Hornberger
Rainer Spriestersbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of EP1362046A1 publication Critical patent/EP1362046A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the invention relates to new compounds that bind to integrin receptors, their production and use.
  • Integrins are cell surface glycoprotein receptors that mediate interactions between similar and different cells as well as between cells and extracellular matrix proteins. They are involved in physiological processes such as Embryogenesis, hemostasis, wound healing, immune response and formation / maintenance of tissue architecture are involved.
  • Disorders in the gene expression of cell adhesion molecules and functional disorders of the receptors can contribute to the pathogenesis of many diseases, such as tumors, thromboembolic events, cardiovascular diseases, lung diseases, diseases of the CNS, the kidney, the gastrointestinal tract or inflammation.
  • Integrins are heterodimers each consisting of an ⁇ and a ⁇ -membrane subunit, which are non-covalently linked. To date, 16 different ⁇ and 8 different ⁇ subunits and 22 different combinations have been identified.
  • Integrin ⁇ v ß 3f also called vitronectin receptor, mediates adhesion to a large number of ligands - plasma proteins, extracellular matrix proteins, cell surface proteins - the majority of which contain the amino acid sequence RGD (Cell, 1986, 44, 517-518; Science 1987, 238, 491-497), such as, for example, vitronectin, fibrinogen, fibronectin, from Willebrand factor, thrombospondin, osteopontin, lainein, collagen, thrombin, tenascin, MMP-2, bone sialo protein II, various viral, fungal, parasitic and bacterial proteins , natural inte- grin antagonists such as disintegrins, neurotoxins - Mambin - and B lutegelproteine - decorsin, ornatin - as well as some non-RGD-Li ligands, such as Cyr-61 and PECAM-1 (L.
  • Integrin ⁇ n b ß 3 also known as platelet fibrinogen receptor, recognizes fibronectin, vitronectin, thrombospondin, von Willebrand factor and fibrinogen.
  • Integrin ⁇ v ß 3 is expressed, inter alia, on endothelial cells, platelets, monocytes / macrophages, smooth muscle cells, some B cells, fibroblasts, osteoclasts and various tumor cells, such as melanomas, glioblastomas, lung, breast, prostate and bladder carcinomas, Osteosarcomas or neuroblastomas.
  • An increased expression is observed under various pathological conditions, such as in the prothrombotic state, in the case of vascular injury, tumor growth or metastasis or reperfusion and on activated cells, in particular on endothelial cells, smooth muscle cells or macrophages.
  • Cardiovascular diseases such as atherosclerosis, restenosis after vascular injury, and angioplasty (neointima formation, smooth muscle cell migration and proliferation) (J. Vase. Surg. 1994, 19, 125-134; Circulation 1994, 90, 2203-2206),
  • Angiogenesis-associated microangiopathies such as diabetic retinopathy or rheumatic arthritis (Ann. Rev. Physiol 1987, 49, 453-464; Int. Ophthalmol. 1987, 11, 41-50; Cell 1994, 79, 1157-1164; J. Biol. Chem. 1992, 267, 10931-10934),
  • Cancer such as tumor metastasis or tumor growth (tu or induced angiogenesis) (Cell 1991, 64, 327-336; Nature 1989, 339, 58-61; Science 1995, 270, 1500-1502), Osteoporosis (bone resorption after proliferation, chemotaxis and adhesion of osteoclasts to bone matrix) (FASEB J. 1993, 7, 1475-1482; Exp. Cell Res. 1991, 195, 368-375, Cell 1991, 64, 327-336),
  • Pathogen protein e.g. HIV-1 tat
  • processes e.g. angiogenesis, Kaposi's sarcoma
  • Advantageous ⁇ v ⁇ 3 integrin receptor ligands bind to the integrin ⁇ v ⁇ 3 receptor with an increased affinity.
  • ⁇ v ß 3 -lntegrinrezeptorliganden have, compared to the integrin ⁇ v SS3 additionally an increased selectivity on and with respect to the integrin ⁇ nbß 3 at least a factor 10 less effective, preferably at least by a factor of one hundredth
  • WO 00/61551 describes substituted pyrimidinone derivatives as integrin ligands which already have good activities and selectivities. However, there is still a need to further improve the activities and selectivities as well as the pharmacokinetic properties of the intergrin ligands.
  • the object of the invention was therefore to provide new integrin receptor ligands with advantageous properties, such as improved activities, selectivities and pharmacokinetic properties.
  • L is a structural element of the formula I L
  • T is a group of COOH or an ester hydrolyzable to COOH and -ü- - ( CR L 1 R L 2 ) a- (V) b - (CR L 3 R 4 ) c- ( w L ) d - (CR L 5R L 6 ) e _ (XL) f _ mean in which
  • R ⁇ l, R y l * independently of one another hydrogen, a branched or unbranched, optionally substituted C ⁇ -C 6 -alkyl-, -C-C 6 -alkoxyalkyl-, C 2 -C 6 -alkenyl-, C 3 -C ⁇ 2 - Alkynyl, CO-C 6 alkyl, CO-0-C 6 alkyl or S0 2 -C 6 alkyl radical or an optionally substituted C 3 -C 7 cycloalkyl, aryl, arylalkyl -, CO-O-alkylene-aryl, CO-alkylene-aryl, CO-aryl, S0 2 -aryl, hetaryl, CO-hetaryl or S0 2 -alkylene-aryl radical, RL 7 , RL 8 independently of one another hydrogen, halogen, a hydroxyl group, a branched or unbranched, optionally substituted Ci-C ö alky
  • R L 9 is hydrogen, a hydroxy group, CN, halogen, a branched or unbranched, optionally substituted Ci-C ö alkyl group, an optionally substituted C 3 -C 7 cycloalkyl, aryl, heteroaryl or arylalkyl radical, optionally substituted with Ci- C — alkyl or aryl substituted C 2 -C 6 -alkynyl— or C 2 —C 6 -alkenyl, an optionally substituted ⁇ —C ⁇ 2 —bicycloalkyl—, Ci-C ⁇ -alkylene-C 6 -C ⁇ 2 —bicycloalkyl— , C 7 -C 2 o ricycloalkyl- or -C-C 6 alkylene-C 7 -C 20 tricycloalkyl radical, or a 3- to 8-membered, saturated or unsaturated heterocycle substituted with up to three identical or different radicals, which can contain up to three different or identical hetero
  • R 9 * L is hydrogen, hydroxy, CN, halogen, a branched or unbranched, optionally substituted Ci-C ö alkyl group, an optionally substituted C 3 -C 7 cycloalkyl, aryl, heteroaryl or arylalkyl radical, optionally substituted with C 1 _c 4 _alkyl or aryl substituted C 2 -C 6 alkynyl- or C 2 -Ce alkenyl, an optionally substituted C 6 -C 2 bicycloalkyl, Ci-C ß alkylene-C 6 -C 2 -C bicycloalkyl, CC 20 tricycloalkyl or -C 6 alkylene -C 7 -C 2 o-tricycloalkyl, or a 3- to 8-membered, saturated or unsaturated heterocycle substituted with up to three identical or different radicals, which may contain up to three different or identical heteroatoms O, N, S, where two radicals together can form
  • W L is an optionally substituted 4 to 11-membered mono- or polycyclic aliphatic or aromatic hydrocarbon which can contain up to 6 double bonds and up to 6 heteroatoms selected from the group N, 0, S,
  • L, X independently of one another -CO-, -CO-NR L 10 -, -NR L 10 -CO-,
  • R L 10 is hydrogen, koxyalkyl- a branched or unbranched, optionally substituted C ⁇ -C6 alkyl, Ci-C ⁇ -Al, C 2 -C 6 alkenyl, C 3 -C ⁇ 2 alkynyl, CO-C -C ⁇ -alkyl, CO-O-Ci-C ⁇ -alkyl or S0 2 -C ⁇ -C 6 alkyl or an optionally substituted C 3 -C 7 cycloalkyl, CO-O-alkylene-aryl, CO-alkylene aryl, aryl alkyl, CO aryl, S0 2 aryl, hetaryl, CO hetaryl, hetarylalkyl or S0 2 alkylene aryl radical, or RL 10 and a radical selected from the group RL 1 , RL 2 / R L 3 » R 4 > R L 5 or R L 6 together form an optionally substituted 4 to 8-membered heterocycy-
  • RL 11 - RL 12 independently of one another hydrogen, a hydroxyl group, a branched or unbranched, optionally substituted Ci-C ß alkyl, -C-C 4 alkoxy, C 2 -C 6 alkenyl, C 2 -C 6 - Alkynyl or alkylene-cycloalkyl or an optionally substituted C 3 -C -cycloalkyl, aryl, arylalkyl, hetaryl or hetarylalkyl radical,
  • R L 13 is hydrogen, a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl, C 2 -C 6 kenyl- -Al-, C 2 -C 6 alkynyl or alkylene-cycloalkyl radical or an optionally substituted C 3 - C cycloalkyl, aryl, arylalkyl, hetaryl or hetarylalkyl radical,
  • R L 15 is a branched or unbranched, optionally substituted Cx-C ⁇ -alkyl, alkoxyalkyl, -C-C 6 -alkylene-C 3 -C 7 -cycloalkyl radical, C 6 -C ⁇ 2 —bicycloalkyl-, -C ⁇ -C 6 -Alkylene-C 6 -C ⁇ 2 —bicycloalkyl—, CC 2 o-tricycloalkyl- or C ⁇ -C 6 -alkylene-C 7 -C 20 —tricycloalkyl radical, a C 3 -C substituted with up to three identical or different radicals 7- cycloalkyl, aryl, arylalkyl, hetarylalkyl or 3- to 8-membered, saturated, unsaturated or aromatic heterocycle radical which can contain up to three different or identical heteroatoms O, N, S, two radicals together a fused, saturated, unsaturated or aromatic carbocycle or
  • R 16 L is a branched or unbranched, optionally substituted C ⁇ -C ß 6 alkyl, alkoxyalkyl or Ci-C - alkylene-C 3 -C cycloalkyl group or an optionally substituted C 3 -C 7 cycloalkyl, aryl, Arylalkyl, hetaryl or hetarylalkyl radical,
  • G is a structural element of the formula I G
  • the structural element G can be installed in both orientations and
  • RG 1 'RG 2 independently of one another are hydrogen, CN, N0 2f halogen, a branched or unbranched, optionally substituted Ci-C ⁇ -alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl radical, a branched or unbranched, optionally substituted radical C ⁇ -C 4 alkylene-0R G 4, C 1 -C 4 -Alky- len-CO-OR G 4, C ⁇ -C 4 -alkylene-CO-RG 4, C ⁇ -C 4 -Alky - len-S0 2 -NR G 5 R G 5 , -C-C 4 -alkylene-C0-NR G 5 R G 6 , -CC-C 4 -alkylene-NR- 5 R G 6 or C ⁇ -C -alkylene- SR G 4 , an optionally substituted C 3 -C 7 cycloalkyl, C 3 -C heterocycloalkyl, C 3 -
  • R- 3 is hydrogen, a hydroxyl group, CN, a branched or unbranched, optionally substituted C 1 -C 4 -alkyl or C 1 -C 4 alkoxy radical or an optionally substituted C 3 -C 7 cycloalkyl, -0-C 3 -C-cycloalkyl radical, aryl, -O-aryl, arylalkyl or -O-alkylene-aryl radical,
  • R G 4 is hydrogen, a branched or unbranched, optionally substituted Ci-C ⁇ -alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 5 alkylene-C 1 -C 4 - Alkoxy, mono- and bis-alkylaminoalkylene or acylaminoalkylene or an optionally substituted aryl, heterocycloalkyl, heterocycloalkenyl, heteraryl, C 3 -C 7 cycloalkyl, C 1 -C 4 alkylene-C 3 -C 7 -cycloalkyl-, arylalkyl-, -C-C 4 -alkylene-heterocycloalkyl-, -C-C 4 -alkylene-heterocycloalkeny1 or hetarylalkyl radical,
  • RG 5 , RG 6 independently of one another hydrogen, a branched or unbranched, optionally substituted Ci-Ca alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C ! -C 5 -alkylene -C-C 4 -alkoxy, mono- and bis-alkylaminoalkylene or acylaminoalkylene or an optionally substituted aryl, heterocycloalkyl, heterocycloalkenyl, hetaryl, C 3 -C 7 cycloalkyl, C 1 -C 4 -alkylene-C3-C 7 -cycloalkyl-, arylalkyl-, C 1 -C 4 -alkylene-heterocycloalkyl-, C 1 -C 4 - alkylene-heterocycloalkenyl or hetarylalkyl radical, or a radical -S0 2 -R G 4 ,
  • R G 4 * is independent of R G 4 R G 4,
  • a structural element containing at least one atom which can form hydrogen bonds under physiological conditions as a hydrogen acceptor, with at least one hydrogen acceptor atom along the shortest possible Chen path along the structural element framework has a distance of 4 to 13 atomic bonds to structural element G,
  • a halogen radical is understood to mean, for example, F, Cl, Br or I for all radicals and substituents of the present invention, unless stated otherwise.
  • substituted radicals are understood to mean the corresponding unsubstituted and substituted radicals.
  • substituents are not specified in more detail, up to 5 substituents, for example selected from the following group, are suitable independently of one another:
  • substituted hetaryl and heterarylalkyl radicals of the present invention in addition to the above list of substituents, two substituents of the hetaryl part can form a fused 5- to 7-membered, unsaturated or aromatic carbocycle.
  • T is understood to mean a group of COOH or a radical that can be hydrolyzed to COOH.
  • a residue that can be hydrolyzed to COOH is understood to mean a residue which, after hydrolysis, changes into a COOH group.
  • the group is an example of a radical T which can be hydrolyzed to COOH
  • R 1 has the following meaning:
  • M is a metal cation, such as an alkali metal cation, such as lithium, sodium, potassium, the equivalent of an alkaline earth metal cation, such as calcium, magnesium and barium or an environmentally compatible organic ammonium ion such as, for example, primary, secondary, tertiary or quaternary C 1 -C 4
  • organic ammonium ion such as, for example, primary, secondary, tertiary or quaternary C 1 -C 4
  • a branched or unbranched, optionally substituted with halogen -CC 8 alkoxy such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1, 1-dimethylethyloxy, especially methoxy , Ethoxy, 1-methylethoxy, pentoxy, hexoxy, heptoxy, octoxy, difluoromethoxy, trifluoromethoxy, chlorodifluoromethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy,
  • halogen -CC 8 alkoxy such as methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1, 1-dimethylethyloxy, especially methoxy , Ethoxy, 1-methylethoxy, pentoxy, hexoxy, heptoxy, octoxy, difluoromethoxy
  • a branched or unbranched, optionally substituted with halogen dC 4 -alkylthio radical such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio or 1, 1-dimethylethylthio radical
  • an optionally substituted -O-alkylene-aryl radical such as -O-benzyl R 1 furthermore a radical - (0) ml -N (R 2 ) (R 3 ), in which ml represents 0 or 1 and R 2 and R 3 , which may be the same or different, have the following meaning:
  • C ⁇ -C 6 alkyl such as methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dirnethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dirnethylpropyl , 1,1-dirnethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 1, 1-dirnethylbutyl, 2.2 -Dimethylbutyl, 3,3-dimethylbutyl, 1, 1, 2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethylbutyl, 2-ethylbutyl or 1-ethyl-2-methylpropyl or the corresponding substituted radicals, preferably methyl, e
  • C 2 -C 6 alkenyl such as vinyl, 2-propenyl, 2-butenyl, 3-butenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 2-pentenyl, 3-pentenyl, 4- Pentenyl, l-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, l, 2-dimethyl-2-propenyl, l-ethyl-2-propenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl1- 2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 3-methyl-1-3-pentenyl, 4-methyl-3-pentenyl, l-methyl-4
  • C 2 -C 6 - lkinylrest A such as ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, l-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, l-methyl-3 -butinyl, 2-methyl-3-butynyl, l-methyl-2-butynyl, 1, l-dimethyl-2-propynyl, l-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, l-methyl-2-pentynyl, l-methyl-2-pentynyl, l-methyl-3-pentynyl, l-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4- pentynyl, 3-methyl
  • C 3 -C 8 cycloalkyl such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, cyclooctyl or the corresponding substituted radicals,
  • P enyl radical optionally mono- or polysubstituted, for example mono- to trisubstituted by halogen, nitro, cyano, C 4 -alkyl, C 4 haloalkyl, C ⁇ -C 4 -alkoxy, C 4 - Halogenalkoxy or -CC 4 alkylthio such as 2-fluorophenyl, 3-chlorophenyl, 4-bromophenyl, 2-methylphenyl, 3-nitrophenyl, 4-cyanophenyl, 2-trifluoromethylphenyl, 3-methoxyphenyl, 4-trifluoroethoxypheny1, 2-methylthiophenyl, 2,4-dichlorophenyl, 2-methoxy-3-methylphenyl, 2,4-dimethoxyphenyl, 2-nitro-5-cyanophenyl, 2,6-difluorophenyl,
  • Preferred radicals T are -COOH, -CO-O-Ci-Cg-alkyl or -CO-0-benzyl.
  • coefficients a, c and e of structural element -U- independently denote 0, 1, 2 or 3, preferably 0, 1 or 2, particularly preferably 0 or 1.
  • the sum of the coefficients a, c and e is less than 5.
  • the coefficients a, c and e are independently 0 or 1. In the case of further, particularly preferred structural elements -U-, the coefficients b, d and f are equal to 0.
  • Preferred halogen radical for RL 1 , RL 2 , R L 3 , RL 4 , R L 5 , RL 6 , R L 7 or R 8 is F.
  • Ci-C ⁇ -alkyl radicals for R L X , R L 2 , R L 3 , R L 4 , R L 5 , R L 6 , R L 7 or R L 8 in structural element L are independently, for example, methyl, ethyl , Propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, 1, 1-dimethylpropyl, 2.2 -Dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl , 1,1,2-trimethylpropyl, 1,2,2-trimethylprop
  • Branched or unbranched C 1 -C 6 alkylene-C 3 -C 7 cycloalkyl radicals are composed, for example, of branched or unbranched Ci-C ⁇ alkylene radicals and the above-mentioned C 3 -C cycloalkyl radicals.
  • Preferred, optionally substituted aryl radicals for R 1 , R L 2 , R L 3 , R L 4 , R L 5 , R L 6 , RL 7 or R L 8 in structural element L are, independently of one another, optionally substituted phenyl, 1-naphthyl or 2 -Naphthyl.
  • Preferred, optionally substituted arylalkyl radicals for R 1 , R L 2 , R L 3 , R L 4 , RL 5 , RL 6 , R L 7 or R L 8 in structural element L are, independently of one another, optionally substituted benzyl or ethylene phenyl (homobenzy1).
  • Hetaryl radicals for R L X , RL 2 , RL 3 , RL 4 , RL 5 , R L 6 , R L 7 or R L 8 in structural element L are, for example, radicals such as 2-pyridyl, 3-pyridyl, 4-pyridyl, independently of one another , 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-oxazolyl, 4-oxazolyl, 5-0xazolyl, 2 -Pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 6-pyrimidyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 2-imidazolyl, 4-imidazolyl, 5 -Imidazolyl
  • U nder substituted hetaryl radicals for R 1, R L 2, R L 3, R L 4, R L 5, R L 6, R L 7 or R L 8 in structural element L are as described above generally for terminal, substituted hetaryl, also fused derivatives of the above-mentioned hetaryl radicals are understood, such as, for example, indazole, indole, benzothiophene, benzofu ran, indoline, benzimidazole, benzothiazole, benzoxazole, quinoline, 2,3-dihydro-l-benzofuran, furo [2,3] pyridine, furo [3,2] pyridine or isoquinoline.
  • R L 2 Under Hetarlyalkylresten be R L: R L 2, R L 3, R L 4, R L 5, R L 6, R L 7 or R L, means radicals in structural element L 8, which, for example, Ci-C ⁇ -alkylene and in the hetaryl radicals described above, such as the radicals -CH 2 -2-pyridyl, -CH 2 -3-pyridyl, -CH 2 -4-pyridyl, -CH 2 -2-thienyl, -CH 2 -3- Thienyl, -CH 2 -2-thiazolyl, -CH 2 -4-thiazolyl, CH 2 -5-thiazolyl, -CH 2 -CH 2 -2-pyridyl, -CH 2 -CH 2 -3-pyridyl, -CH 2 -CH 2 -4-pyridyl, -CH 2 -CH 2 -2-thienyl, -CH 2 -CH 2 -3-thien
  • two radicals R L 1 and R L 2 or R L 3 and R L 4 or R L 5 and R L 6 or R L 7 and R L 8 can each independently form a 3 to 7-membered, optionally substituted, saturated radical or unsaturated carbocycle or heterocycle which can contain up to three heteroatoms from the group 0, N or S.
  • the rest - (CH 2 ) w - ( ⁇ L) y-RL 9 which the residues RL 1 , R L 2 , R L 3 , RL 4 , R L 5 and R L 6 can independently mean, consists of one C 0 -C 4 alkylene radical, optionally a binding element Y L selected from the group
  • Ry 1 '1 * Ry are independently hydrogen, a branched or unbranched, optionally substituted Ci-C ⁇ alkyl, Ci-C ⁇ -alcohol xyalkyl, C 2 -C 6 alkenyl, C 3 alkynyl -C ⁇ 2 , CO-Cx-C ⁇ -alkyl, CO- 0 -CC -C 6 alkyl or S0 2 -C ⁇ -C 6 alkyl radical or an optionally substituted C 3 -C 7 cycloalkyl, aryl, arylalkyl, CO -O-alkylene-aryl, CO-alkylene-aryl, CO-aryl, S0 2 -aryl, hetaryl, CO-hetaryl or S0 2 -alkylene-aryl radical, preferably hydrogen, methyl, cyclopropyl, allyl or propargyl, particularly preferably hydrogen or methyl, and
  • Hydrogen a hydroxyl group, CN, halogen, a branched or unbranched, optionally substituted C 1 -C 6 -alkyl radical, an optionally substituted C 3 -C 7 cycloalkyl, aryl, heteroaryl or arylalkyl radical, one optionally with C 1 -C 4 - Alkyl or aryl substituted C 2 -C 6 alkynyl or C 2 -C 6 alkenyl, an optionally substituted C 6 -C 2 bicycloalkyl, C 6 -C alkylene C 6 -C 2 bicycloalkyl, C 7 -C 2 o-Tricycloalkyl- or -C-C 6 alkylene-C 7 -C 20 tricycloalkyl radical, or a 3 to 8 membered, saturated or unsaturated heterocycle substituted with up to three identical or different radicals , which can contain up to three different or identical heteroatoms O, N, S, where two radicals together
  • R L 9 and Ry 1 or Ry 1 * together can form a saturated or unsaturated C 3 -C heterocycle which can optionally contain up to two further heteroatoms selected from the group 0, S or N.
  • the radicals R L 9 and R y 1 or R y 1 * together form a cyclic amine as a C 3 -C 7 heterocycle, in the event that the radicals are bonded to the same nitrogen atom, such as, for example, N -pyrrolidinyl, N- Piperidinyl, N-hexahydroazepinyl, N-morpholinyl or N-piperazinyl, where the free amine protons carry in heterocycles, such as N-piperazinyl, for example, the free amine protons by common amine protective groups, such as methyl, benzyl, Boc (tert-butoxycarbonyl), Z (benzyloxycarbonyl), tosyl, -S0 2 -C ⁇ -C 4 alkyl, -S0 2 -phenyl or -S0 2 -benzyl can be replaced.
  • nitrogen atom such as, for example, N -pyrrolidinyl, N- Piperidinyl, N-
  • Preferred radicals - (CH 2 ) w - (Y L ) yR L 9 for RL 1 , R L 3 or R L 5 in structural element L are optionally substituted side chains of the natural amino acids, preferably optionally substituted side chains of the amino acids Ser, Thr, Tyr, Asp, Asn, Glu, Gin, Cys, Met, Lys or Orn, optionally substituted Side chains of unnatural amino acids, as described, for example, in catalogs from the companies Bachern 1999, Novabiochem 1999, Neosystem 1997/98 and Advanced ChemTech 1999.
  • Side chains of natural ⁇ -amino acids are understood to mean the side chains including the ⁇ -C atom.
  • Unnatural amino acids are, for example, ⁇ -amino acids.
  • side chains are understood to mean the side chains including the ⁇ -C atom.
  • Substituted side chains are also understood to mean, for example, side chains which have a protective group on a functional group of the side chain, such as -NH 2 , -SH, -OH or -COOH.
  • the optionally substituted radical - (CH 2 ) W -R L 9 * which the radicals R L 7 and R L 8 can mean independently of one another, is composed of an optionally substituted Co-C 4 alkylene radical and the radical R L 9 * together, where R L 9 * has the following meaning:
  • Hydrogen a hydroxyl group, CN, halogen, a branched or unbranched, optionally substituted C 1 -C 6 -alkyl radical, an optionally substituted C 3 -C -cycloalkyl—, aryl—, preferably phenyl or naphthyl, heteroaryl or arylalkyl radical substituted optionally substituted with C J -C 4 TAlkyl or aryl C kinyl- 2 -CE Al or C 2 -C 6 alkenyl, an optionally substituted C 6 -C 12 bicycloalkyl, C ⁇ -C 6 alkylene-C 6 -C ⁇ 2 —bicycloalkyl—, C 7 _c 20 -tricycloalkyl or C ⁇ -C 6 alkylene-C 7 -C 2 o-tricycloalkyl radical, or a 3- to 8-membered group substituted by up to three identical or different radicals, saturated or unsaturated heterocycle, which can
  • An optionally substituted 4 to 11-membered mono- or polycyclic aliphatic or aromatic hydrocarbon which can contain up to 6 double bonds and up to 6 heteroatoms, selected from the group N, 0, S, is preferably optionally substituted arylene for W L , such as optionally substituted phenylene or naphthylene, optionally substituted hetarylene such as the radicals
  • the coefficient r denotes 0, 1, 2 or 3 and Z 10 and Z 11 independently CH or nitrogen and Z 8 and Z 8 * independently oxygen, sulfur or NH .
  • V orzugêt W L is an optionally substituted Phe nylenrest a radical
  • the coefficient r is 0, 1, 2 or 3
  • Z 8 and Z 8 * are each independently oxygen, sulfur or NH means.
  • Preferred radicals for V L and X L are independently of one another -CO-NR L 10 -, -NR L 10 -CO-, -S0 2 -NR L 10 -, -NR L 10 -SO 2 -, -O-, - CH (NR L 14 -S0 2 -R L 15 ) -, -CH (NR L 14 -CO-R L 15 ) -, -CH (NR L 1 -CO-OR L 16 ) -, CH (NR L 14 -CO-NRL 14 # R L 15 ) -, -CH (CO-R L 15 ) -, -CH (CO-OR L 16 ) - and CH (CO-NR-NR-
  • radicals for v L and X L are independently of one another -CH (NR L 14 -S0 2 -R L 15 ) -, -CH (NR L 14 -C0-R L 15 ) -, -CH (NR L 14 - CO-OR L 16 ) -, CH (NR L 14 -CO-NR L 14 'R L 15 ) -, -CH (CO-R L 15 ) -, -CH (CO-OR L 16 ) - and CH ( CO-NR L 14 R L 15 ) -.
  • the radical R L 10 in structural element L means hydrogen
  • C 1 -C 6 -alkyl radical for example as described above for R L X , preferably methyl
  • Ci-Co alkoxyalkyl radical for example methoxymethylene, ethoxymethylene, t-butoxymethylene, methoxyethylene or ethoxyethylene,
  • C 2 -C 6 alkenyl radical for example as described above for R 1 , preferably allyl, nyl, l-methyl-3-pentynyl, l-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-4-pentynyl, 4-methyl-2- pentynyl, l, l-dimethyl-2-butynyl, 1, l-dimethyl-3-butynyl, 1,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, l-ethyl- 2-butynyl, l-ethyl-3-butynyl, 2-ethyl-3-butynyl and l-ethyl-l-methyl-2-propynyl, preferably popargyl,
  • CO-C 6 -C 6 -alkyl CO-O-C 1 -C 6 -alkyl or S0 2 -C 6 -C 6 -alkyl radical, which is in each case from the corresponding group CO-, CO-O- or S0 2 - and composed, for example, of the Ci-C ß -alkyl radicals described above,
  • CO-O-alkylene-aryl an optionally substituted CO-O-alkylene-aryl, CO-alkylene-aryl, CO-aryl, S0 2 -aryl, CO-hetaryl or S0 2 -alkylene-aryl radical, each consisting of the corresponding group CO-, CO-O- or S0 2 - and composed, for example, of the corresponding arylalkyl, aryl, hetarylalkyl and hetaryl radicals described for R L 1 .
  • R L 10 and a radical selected from the group RL 1 , R L 2 , R L 3 , R L 4 , R L 5 or R L 6 together form an optionally substituted 4 to 8-membered heterocycle which is up to can contain five identical or different heteroatoms 0, N or S.
  • radicals for R L 10 are hydrogen, methyl, cyclopropyl, allyl and propargyl.
  • U nder a branched or unbranched Ci-C ⁇ -alkyl, C2-C6-Al kenyl-, C 2 -C 6 alkynyl or C ⁇ -C6-alkylene-C 3 -C 7 cycloalkyl group or an optionally substituted C 3 -C 7 -cycloalkyl—, aryl—, arylalkyl, hetaryl or hetarylalkyl radical, for R L U or R L 12 are understood independently of one another, for example, the corresponding radicals mentioned above for R L X.
  • U nder a branched or unbranched C ⁇ -C 4 alkoxy are for R 11 or R L L 12 independently of one another example, the radicals methoxy, ethoxy, propoxy, l-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy or 1, 1-Dimethylethoxy understood.
  • R L L 14 and R 14 ' are independently hydrogen, a branched or unbranched, unsubstituted or substituted C ⁇ -C 6 alkyl or C 3 alkynyl group or a 2 -C ⁇ gege ⁇ appropriate, substituted C 3 -C 7 - Cycloalkyl, aryl, hetaryl or arylalkyl radical.
  • radicals for R L 14 and R L 14 ' are, independently of one another, hydrogen, methyl, cyclopropyl, allyl or propargyl.
  • R L 15 denotes a branched or unbranched, optionally substituted
  • C 1 -C 6 -alkyl radical as described above for R L 1 , preferably a branched or unbranched, optionally substituted C 1 -C 4 -alkyl radical, particularly preferably n-butyl, 2-methylpropyl, 1-methylethyl,
  • C 6 -Ci 2 bicycloalkyl or C 7 -C 20 tricycloalkyl such as, for example, bicyclo [4.4.0] decanyl, bicyclo [2.2.2] octanyl, bicyclo [3.2.1] octanyl, indanyl, adamantyl, norbornyl , Noradamanthyl or camphor-10-yl,
  • -C-C 6 -alkylene-C 6 -C ⁇ 2 -cycloalkyl- or -C-C 6 alkylene-C 7 -C 20 -tricycloalkyl radical such as -CH 2 -Bicyclo [4.4.0] decanyl, -CH 2 - Bicyclo [2.2.2] octanyl, -CH 2 -Bicyclo [3.2.1] octanyl, -CH 2 -indanyl, -CH 2 -adamantyl, -CH 2 -norbornyl, -CH-noradamanthyl or -CH 2 -Cam- pher-10-yl,
  • R L 15 and R L 14 or R L 14 * together can form a saturated or unsaturated C 3 -C 7 heterocycle which may optionally contain up to two further heteroatoms selected from the group O, S or N.
  • the radicals R L 15 and R L 14 or R L 14 * together form a cyclic amine radical as a C 3 -C 7 heterocycle, in the event that the radicals are bonded to the same nitrogen atom, such as N-pyrrolidinyl, N- Piperidinyl, N-hexahydroazepinyl, N-morpholinyl or N-piperazinyl, where the free amine protons carry in heterocycles, such as, for example, N-piperazinyl, the free amine protons by common amine protective groups, such as methyl, benzyl, Boc (tert-butoxycarbonyl), Z ( Benzyloxycarbonyl), tosyl, -S0 2 -C ⁇ -C 4 alkyl, -S0 2 -phenyl or -S0 2 -Benzyl can be replaced.
  • nitrogen atom such as N-pyrrolidinyl, N- Piperidinyl, N-hexahydroazepiny
  • the cyclic amine residue NR L 15 R L 14 or NR L 15 R L 14 * can also be part of an amide, sulfonamide, urethane or other possible composite structural element.
  • Preferred radicals for R L 15 are a branched or unbranched, optionally substituted C 1 -C 4 alkyl or -CH 2 -C 5 -C 7 cycloalkyl radical, an optionally substituted C 5 -C 7 cycloalkyl, phenyl , 1-naphthyl-, 2-naphthyl-, -CH 2 -naphthyl-, pyridyl, -CH 2 - pyridyl-, ethylenephenyl-, thienyl-, -CH 2 -thienyl-, oxazolyl-, -CH 2 -oxazolyl-, Isoxazolyl, CH 2 isoxazolyl, quinolinyl, iso quinolinyl, CH 2 quinolinyl, CH 2 isoquinolinyl, adamantyl, CH 2 adamantyl, norbornyl, CH 2 norborn
  • C 1 -C 6 alkyl, alkoxyalkyl or C 1 -C 6 alkylene C 3 -C 7 cycloalkyl radical or an optionally substituted C 3 -C 7 cycloalkyl, aryl -, Arylalkyl, hetaryl or hetarylalkyl radicals for R L 16 are, for example, the corresponding radicals mentioned above for R L 15 , preferably hydrogen, a branched or unbranched, optionally substituted -CC alkyl or - CH 2 -C 5 -C cycloalkyl, an optionally substituted C 5 -C 7 cycloalkyl, phenyl, 1-naphthyl, 2-naphthyl, -CH 2 -Naphtyl-, benzyl-, pyridyl, -CH 2 -pyridyl-, ethylenephenyl-,
  • radicals for R L 16 are a branched or un ⁇ branched, unsubstituted or substituted C ⁇ -C alkyl and GE ⁇ optionally substituted benzyl.
  • radicals R L X , RL 2 , R L 3 , R L 4 , R L 5 or R L 6 independently of one another denote hydrogen or methyl and the indices b, d and f equal 0 or 1 with the proviso that the radicals V L or X L independently of one another are a radical -CH (NR L 14 -S0 2 -R L 15 ) -, -CH (NR L 14 -CO-R L 15 ) -, -CH (NR L 14 -C0-0R L 16 ) -, -CH (NR L 1 -CO-NR L 14 'R L 15 ) -, -CH (CO-OR L 16 ) - or -CH (CO-NR L 14 R 15 ) - mean.
  • a particularly preferred structural element -U- is the methylene group -CH 2 -.
  • R 7 and R L L 8 are independently hydrogen, a branched or unbranched, unsubstituted or substituted C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or C ⁇ -C 6 -alkylene-C 3 -C 7 -cycloalkyl radical, an optionally substituted radical - (CH 2 ) W -R L 9 * , or an optionally substituted aryl, arylalkyl, hetaryl or hetarylalkyl radical.
  • the radical R L 7 is hydrogen and the radical R L 8 is an optionally substituted radical - (CH 2 ) W -R L 9 *, where w is preferably 1, 2 or 3, particularly preferably 1 or 2 and R L 9 * denotes an optionally substituted aryl radical, preferably optionally substituted phenyl or naphthyl.
  • Preferred structural elements L are composed of at least one preferred radical of the radicals belonging to structural element L, while the remaining radicals are widely variable.
  • Particularly preferred structural elements L are composed of the preferred residues of structural element L.
  • G represents a structural element of the formula I G , wherein the structural element G can be installed in both orientations.
  • Z G means oxygen, sulfur or NRQ 3 , preferably oxygen.
  • substitution pattern is defined as in formula I GB ,
  • the structural element G can be installed in both orientations.
  • the substitution pattern is defined as in formula I GB and the structural element G is installed in such a way that the structural element E is connected to the 4-carbon position and that the structural element L is connected to the 1-nitrogen position.
  • R G 1 and R G 2 in structural element G independently of one another are hydrogen, CN, N0 2 , halogen, a branched or unbranched, optionally substituted
  • C 1 -C 6 -alkyl such as optionally substituted methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1, 1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 1,2 -Dimethylpropyl, 1, 1-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 1,1 -Dimethylbutyl, 2,2-dimethylbutyl, 3, 3-dimethylbutyl, 1, 1, 2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethylbutyl, 2-ethylbutyl or l-ethyl-2-methylpropyl, C 2 -C 6 alkenyl, such as optionally
  • C 2 -C 6 alkynyl such as optionally substituted ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, l-methyl-2-propynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1- Methyl-3-butynyl, 2-methyl-3-butynyl, l-methyl-2-butynyl, 1, l-dimethyl-2-propynyl, l-ethyl-2-propynyl, 2-hexynyl, 3-hexynyl, 4- Hexynyl, 5-hexynyl, l-methyl-2-pentynyl, l-methyl-2-pentynyl, l-methyl-3-pentynyl, l-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl- 4-pentynyl, 3-
  • C 3 -C 7 cycloalkyl such as optionally substituted cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl, C 3 -C 7 heterocycloalkyl such as optionally sub ⁇ stitutechnischs aziridinyl, Diaziridinyl, oxiranyl, Oxaziridinyl, oxetanyl, thiiranyl, thietanyl, pyrrolidinyl, piperazinyl, mor- pholinyl, piperidinyl, tetrahydrofuranyl, tetrahydropyranyl, 1,4-dioxanyl, hexahydroazepinyl, Oxepanyl, 1,2-oxathiolanyl or oxazolidinyl,
  • C 3 -C 4 heterocycloalkenyl such as optionally substituted azirinyl, diazirinyl, thiirenyl, thietyl, pyrrolinyls, oxazolinyls, azepinyl, oxepinyl, ⁇ -pyranyl, ⁇ -pyranyl, ⁇ -pyranyl, dihydropyranyl, 2,5-dihydro -pyrrolinyl or 4,5-dihydro-oxazolyl,
  • a branched or unbranched, optionally substituted -CC 4 alkylene-C 3 -C cycloalkyl radical which is, for example, branched or unbranched Czwe-C 4 alkylene radicals such as methylene, ethylene, propylene, n-butylene, iso-butylene or t-butylene and, for example, the above-mentioned C 3 -C cycloalkyl radicals,
  • a branched or unbranched optionally substituted C 1 -C 4 -alkylene-C 3 -C -heterocycloalkyl or C 1 -C 4 -alkylene-C 3 -C 7 -heterocycloalkenyl radical which is composed of optionally substituted C 1 -C 4 -alkylene radicals , such as methylene, ethylene, propylene, n-butylene, iso-butylene or t-butylene and, for example, the aforementioned C 3 -C 7 heterocycloalkyl or C 3 -c heterocycloalkenyl radicals, the radicals which are preferred in the cyclic part contain one or two heteroatoms selected from the group N, O or S and up to two double bonds,
  • Aryl radical preferably optionally substituted phenyl, 1-naphthyl or 2-naphthyl,
  • Arylalkyl radical preferably optionally substituted benzyl or ethylenephenyl (homobenzyl),
  • Hetaryl radical preferably optionally substituted 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furyl, 3-furyl, 2-pyrrolyl, 3-pyrrolyl, 2-thienyl, 3-thienyl, 2-thiazolyl, 4 -Thiazolyl, 5-thiazolyl, 2-oxazolyl, 4-0xazolyl, 5-0xazolyl, 2-pyrimidyl, 4-pyrimidyl, 5-pyrimidyl, 6-pyrimidyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 3-isothiazolyl , 4-isothiazolyl, 5-isothiazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 3-isoxazolyl, 4-isoxazolyl, 5-is
  • Hetarylalkyl radical preferably optionally substituted -CH 2 -2-pyridyl, -CH 2 -3-pyridyl, -CH 2 -4-pyridyl, -CH 2 -2-thienyl, -CH 2 -3-thienyl, -CH 2 -2 -Thiazolyl, -CH 2 -4-thiazolyl, CH 2 -5-thiazolyl, -CH 2 -CH 2 -2-pyridyl, -CH 2 -CH 2 -3-pyridyl, -CH 2 -CH 2 -4 -Pyridyl, -CH 2 -CH 2 -2-thienyl, -CH 2 -CH 2 -3-thienyl, -CH 2 -CH 2 -2-thiazolyl, -CH 2 -CH 2 -4-thiazolyl or -CH 2 -CH 2 -5-thiazolyl or
  • radicals R G 1 and RQ 2 together can form an optionally substituted, saturated, unsaturated or aromatic 3 to 9-membered carbocycle, carbopolycycle, heterocycle or heteropolycycle which can contain up to 4 heteroatoms selected from the group O, N, S. .
  • Preferred radicals for R G 1 in the structural element G are hydrogen, a branched or unbranched, optionally substituted C 1 -C 6 -alkyl radical, preferably CF 3 , C 2 -C 6 alkenyl, C 2 -C 6 alkynyl radical, C 1 -C 4 -alkylene-ORc 4 , optionally substituted aryl, arylalkyl, hetaryl or hetarylalkyl or a radical -O-Rc 4 .
  • Preferred radicals for RQ 2 in the structural element G are hydrogen, CN, halogen, a branched or unbranched, optionally substituted Ci-C ⁇ -alkyl radical, preferably CF 3 , an optionally substituted C 3 -C 7 cycloalkyl, aryl, arylalkyl, Hetaryl or hetarylalkyl radical, a radical -SO-RQ 4 , -S0 2 -RQ 4 , -CO-OR G 4 , -S0 2 -NR G 5 Rc 6 , -C0-NRc 5 R G 6 , - RQ S R C 6 , CO-R G 4 , -C-C 4 -alkylene-C0-0R G 4 , C ⁇ -C 4 -alkylene-S0 2 -NR G 5 R G 6 , C ⁇ -C -alkylene-CO-NR G 5 R G 6 or C 1 -C 4 -alkylene-NR G 5 R G
  • RQ 2 in the structural element G is a branched or unbranched, unsubstituted or substituted C ⁇ -C rest 6 alkyl, an optionally substituted C 3 -C cycloalkyl, aryl, A rylalkyl-, hetaryl or hetarylalkyl radical, a radical -CO-OR G 4 , -CO-NR G 5 R G 6 , -NR G 5 R G 6 , C ⁇ -C 4 -alkylene-CO-NR G 5 R G 6 or C 1 -C 4 -alky- len-NR G 5 G 6 or an optionally substituted C 3 -C 7 heterocycloalkyl, C 3 -C 7 heterocycloalkenyl, C 1 -C 4 alkylene-C 3 -C 7 heterocycloalkyl or C 1 -C 4 -alkylene-C3-C 7 -heterocycloalkenyl radical, with the last four radicals preferred being the
  • R G 3 represents hydrogen, a hydroxyl group, CN, a branched or unbranched, optionally substituted
  • Ci— C ⁇ — alkyl radical as described for example above for RQ 1 ,
  • —0-C 3 -C 7 -cycloalkyl radical an optionally substituted —0-C 3 -C 7 -cycloalkyl radical, —O — aryl or —O — alkylene-aryl radical which is composed, for example, in each case of the group -0- and the corresponding radicals described above for RQ 1 .
  • Ci-C ⁇ -alkyl radical for R G 4 , R G 4 * , R G 5 and RQ 6 are understood independently of one another, for example, to mean the dC ⁇ -alkyl radicals mentioned above for Rcl, plus the radicals heptyl and octyl.
  • Preferred substituents of the branched or unbranched, optionally substituted C 1 -C 8 -alkyl radicals for RQ 4 , RQ 4 *, R G 5 and R G 6 are independently the radicals halogen, hydroxy, Cj . -C 4 - A lkoxy, -CN, -COOH and -CO-0-C ⁇ -C 4 alkyl.
  • Preferred branched or unbranched, optionally substi tuted ⁇ -C ⁇ -C 5 alkylene-C ⁇ -C4-alkoxy radicals for RQ 4, R G 4 *, R G 5 and R G 6 are independently methoxymethylene, ethoxymethylene, t -Butoxymethylene, methoxyethylene or ethoxyethylene.
  • Preferred, branched or unbranched, optionally substituted mono- and bis-alkylaminoalkylene or acylaminoalkylene radicals for R G 4 , RG 4 *, G 5 and RQ 6 are, independently of one another, branched or unbranched, optionally substituted radicals -C 1 -C 4 -alkylene -NH (-C-C 4 alkyl), -C 1 -C4-alkylene-N (-C-C 4 -alkyl) 2 or -C 1 -C 4 -alkylene-NH-CO-C 1 -C 4 - Alkyl.
  • Preferred optionally substituted heterocycloalkyl, heterocycloalkenyl, -C-C-alkylene-heterocycloalkyl or C ⁇ -C 4 -alkylene-heterocycloalkenyl radicals for RG, R G 4 * , R G 5 and R G 6 are independently the one above for R G 1 described C 3 -C 7 heterocycloalkyl, C3-C 7 heterocycloalkenyl, -C-C 4 alkylene-C 3 -C heterocycloalkyl- or -C-C 4 alkylene-C 3 -C -Heterocycloalkenyl residues.
  • heterocycloalkyl, heterocycloalkenyl, C 1 -C 4 alkylene heterocycloalkyl or C 1 -C 4 alkylene heterocycloalkenyl radicals for Rc 4 , R ⁇ 4 *, R G 5 and R Q 6 are, independently of one another, the above for R G 1 described C 3 -C 7 heterocycloalkyl, C 3 -C 7 heterocycloalkenyl, C ⁇ -C 4 alkylene-C 3 -C 7 heterocycloalkyl or C ⁇ -C alkylene-C 3 -C 7 Heterocycloalkenyl radicals, the cyclic part containing one or two heteroatoms selected from the group N, 0 or S and up to two double bonds.
  • R G 5 and RQ 6 can independently represent a radical -S0 2 -RG 4 , -CO-0-RG 4 , -CO-NRG 4 RG 4 * or -CO-RG 4 , where RQ 4 * is one of R G 4 represents independent radical R G 4 .
  • Preferred structural elements G are composed of at least one preferred radical of the radicals belonging to structural element G or the preferred substitution pattern of structural element G, while the remaining radicals are widely variable.
  • Particularly preferred structural elements G are composed of the preferred residues of structural element G.
  • Very particularly preferred structural elements G are composed of the preferred residues of structural element G and the preferred substitution pattern of structural element G.
  • the substitution pattern is as defined in formula I GB , ZG means oxygen, R G 1 means hydrogen, RQ 2 means methyl and the structural element G is installed in such a way that the structural element E is in position 4 -Carbon and that structural element L is connected to the position 1-nitrogen.
  • Structural element B is understood to mean a structural element containing at least one atom which can form hydrogen bonds under physiological conditions as a hydrogen acceptor, at least one hydrogen acceptor atom being at a distance of 4 to 13 atomic bonds to the structural element along the shortest possible path along the structural element framework G.
  • the design of the structural framework of structural element B is widely variable.
  • Atoms which can form hydrogen bonds under physiological conditions as hydrogen acceptors are, for example, atoms with Lewis base properties, such as the heteroatoms nitrogen, oxygen or sulfur.
  • Physiological conditions are understood to mean a pH value that prevails at the location in an organism at which the ligands interact with the receptors.
  • the physiological conditions have a pH of, for example, 5 to 9.
  • the structural element B means a structural element of the formula I B
  • a 4- to 8-membered monocyclic saturated, unsaturated or aromatic hydrocarbon which can contain up to 4 heteroatoms selected from the group 0, N or S, where the ring nitrogen or the carbons which may be present can be substituted independently of one another , with the proviso that at least one heteroato selected from the group 0, N or S is contained in the structural element A, or
  • a 9- to 14-membered polycyclic saturated, unsaturated or aromatic hydrocarbon which can contain up to 6 heteroatoms selected from the group N, O or S, where the ring nitrogen or the carbons which may be present can be substituted independently of one another , with the proviso that at least one heteroatom selected from the group 0, N or S is contained in the structural element A.
  • RA 18 , RA 19 independently of one another are hydrogen, a branched or unbranched, optionally substituted C ⁇ -C 8 -alkyl-, C 2 -C 6 -alkenyl-, C 2 -C 6 -alkynyl-, C ⁇ -C 5 -alkylene- C ⁇ -C 4 alkoxy, mono- and bis-alkylaminoalkylene or acylaminoalkylene or an optionally substituted aryl, heterocycloalkyl, heterocycloalkenyl, hetaryl, c 3 -C 7 cycloalkyl, C 1 -c 4 alkylene C 3 -C 7 cycloalkyl-, arylalkyl-, C ⁇ -C 4 -alkylene-heterocycloalkyl-, C ⁇ -c 4 -alkylene-heterocycloal- kenyl or hetarylalkyl radical, or a radical -S0 2
  • E is a spacer structural element that covalently connects structural element A to structural element G, the number of atomic bonds along the shortest possible path along the structural element framework E being 3 to 12.
  • the structural element A means a structural element selected from the group of structural elements of the formulas I A 1 to I A 19 ,
  • RA 1 , RA 2 independently of one another are hydrogen, CN, halogen, a branched or unbranched, optionally substituted C 6 -C 6 -alkyl or CO-C 6 -C 6 alkyl radical or an optionally substituted aryl, arylalkyl,
  • RA 13 , RA 13 * independently of one another are hydrogen, CN, halogen, a branched or unbranched, optionally substituted C ⁇ -C 6 -alkyl radical or an optionally substituted aryl, arylalkyl, hetaryl, C 3 -C 7 cycloalkyl radical or a residue CO-0-R A 14 , 0-R A 14 , SR A 14 , NR A 15 RA 16 , S0 2 -NR A 15 R A 16 or C0-NR A 15 R A 16 ,
  • R A 14 is hydrogen, a branched or unbranched, optionally substituted C ⁇ -C 6 -alkyl-, alkylene- C ⁇ -C 4 -alkoxy-, C 2 -C 6 -alkenyl-, C 2 -C 6 -alkynyl- or C ⁇ - C 6 alkylene-C 3 -C 7 cycloalkyl radical or an optionally substituted C 3 -C 7 cycloalkyl, aryl, arylalkyl, hetaryl or hetarylalkyl radical,
  • RA 3 'RA 4 independently of one another are hydrogen, - (CH 2 ) n - (X A ) J-RA 12 , or both radicals together form a 3 to 8-membered, saturated, unsaturated or aromatic N-heterocycle which additionally contains two further identical or can contain different heteroatoms 0, N, or S, the cycle optionally being substituted or a further, optionally substituted, saturated, unsaturated or aromatic cycle being fused onto this cycle,
  • n 0, 1, 2 or 3
  • R A 12 is hydrogen, a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl radical, a C 2 -C 6 alkynyl or C 2 -C 6 alkenyl radical optionally substituted with C mit-C 4 alkyl or aryl, or one with up to three identical or different substituted, 3-6 membered, saturated or unsaturated heterocycle, which can contain up to three different or identical heteroatoms O, N, S, C 3 -C 7 cycloalkyl, aryl or heteroaryl, where two radicals together can form an fused, saturated, unsaturated or aromatic carbocycle or heterocycle, which can contain up to three different or identical heteroatoms 0, N, S, and the cycle optionally substituted or on this cycle another, optionally substituted, saturated, unsaturated or aromatic cycle can be fused, or the radical R A 12 forms together with R x x or Rx 1 * a saturated or unsaturated C 3 -C 7 - heterocycle, which may optionally contain up
  • Rx 1 'Rx 1 * independently of one another hydrogen, a branched or unbranched, optionally substituted
  • C -C 6 alkyl optionally substituted C -C 6 alkyl, arylalkyl, C 3 -C 7 cycloalkyl or C 1 -C 4 alkylene C 3 -C 7 cycloalkyl radical or one optionally substituted aryl, hetaryl, heterocycloalkyl or heterocycloalkenyl radical,
  • Hydrogen a branched or unbranched, optionally substituted C ⁇ -C-alkyl-, -CO- 0-C ⁇ -C 4 -alkyl-, arylalkyl-, -CO-O-alkylene-aryl-, -CO-O-allyl-, -CO-C ⁇ -C 4 -alkyl-, -CO-alkylene-aryl-, C 3 -C 7 -cycloalkyl or -CO-allyl radical or in structural element I
  • a 7 both radicals R A 6 and R A 6 * together one optionally substituted, saturated, unsaturated or aromatic heterocycle which, in addition to the ring nitrogen, can contain up to two further different or identical heteroatoms 0, N, S,
  • R A 7 is hydrogen, -OH, -CN, -CONH 2 is a branched or unbranched, optionally substituted C ⁇ -C 4 alkyl, C ⁇ -C 4 alkoxy, C 3 -C 7 cycloalkyl or -0-CO -C ⁇ -C-alkyl radical, or an optionally substituted arylalkyl, -O-alkylene-aryl, -O-CO-aryl, -O-CO-alkylene-aryl or -O-CO-allyl radical, or both radicals R 6 and R A 7 together form an optionally substituted, unsaturated or aromatic heterocycle which, in addition to the ring nitrogen, can contain up to two further different or identical heteroatoms O, N, S,
  • R A 8 is hydrogen, a branched or unbranched, optionally substituted C ⁇ -C-alkyl, C0-C ⁇ -C 4 alkyl, S0 2 -C ⁇ -C 4 alkyl or CO-0-C ⁇ -C alkyl radical or an optionally substituted aryl, CO-aryl, S0 2 aryl, CO-O-aryl, CO-alkylene-aryl, S0 2 -alkylene-aryl, CO-O-alkylene-aryl or alkylene-aryl radical,
  • RA 9 , RA 10 independently of one another are hydrogen, -CN, halogen, a branched or unbranched, optionally substituted C ⁇ -C 6 -alkyl radical or an optionally substituted aryl, arylalkyl, hetaryl, C 3 -C 7 cycloalkyl radical or a residue C0-0-R A 14 , 0-R A 14 , SR A 14 , NR A 15 R A 16 , S0 2 -NR A 15 R A 16 or C0-NR A 15 R A 16 , or both residues R A 9 and R A 10 together in structural element I A 14 are a 5 to 7-membered saturated, unsaturated or aromatic carbocycle or heterocycle which can contain up to three different or identical heteroatoms 0, N, S and optionally substituted with up to three identical or different radicals,
  • R A 11 is hydrogen, -CN, halogen, a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl radical or an optionally substituted aryl, arylalkyl, hetaryl, C 3 -C 7 cycloalkyl radical or a radical CO-O- RA 14 , 0-R A 14 , SR A 14 , NR A 15 RA 16 , S0 2 -NR A 15 RA 16 or CO- NR A 15 RA 16 ,
  • R A 17 is hydrogen or in structural element I A 16 both radicals R A 9 and R A 17 together form a 5 to 7-membered saturated, unsaturated or aromatic heterocycle which, in addition to the ring nitrogen, can contain up to three different or identical heteroatoms O, N, S. and is optionally substituted with up to three identical or different radicals,
  • RA 18 , RA 19 independently of one another are hydrogen, a branched or unbranched, optionally substituted C ⁇ -C ⁇ -alkyl, C 2 -Ce alkenyl, C 2 -C 6 alkynyl, C ⁇ -C 5 -alkylene-C ⁇ -C 4 alkoxy, mono- and bis-alkylaminoalkylene or acylaminoalkylene or an optionally substituted aryl, heterocycloalkyl, heterocycloalkenyl, hetaryl, C 3 -C 7 cycloalkyl, C ⁇ -C 4 alkylene-C 3 -C 7 cycloalkyl, arylalkyl, C ⁇ -C-alkylene-heterocycloalkyl, C ⁇ -C 4 - alkylene-heterocycloalkenyl or hetarylalkyl radical, or a radical -S0 2 -R G 4 , -CO-OR G 4 , -
  • Z 1 'Z 2 ' Z 3 'z 4 independently of one another nitrogen, CH, C-halogen or a branched or unbranched, optionally substituted C-C ⁇ -C 4 alkyl or C-C ⁇ -C alkoxy radical,
  • the structural element A means a structural element of the formulas
  • a branched or unbranched, optionally substituted C 6 -C 6 -alkyl radical for R A X or R A 2, independently of one another, means, for example, the corresponding radicals described above for R G 1 , preferably methyl or trifluoromethyl.
  • the branched or unbranched, optionally substituted radical CO-C ⁇ -C6-alkyl is for R A 1 or R A 2 in the structural elements I A 1 , I A 2 , IA 3 or I A 17, for example from the group CO and the above described for R A 1 or R A 2 , branched or unbranched, optionally substituted C ⁇ -C 6 alkyl radicals together.
  • Optionally substituted hetaryl, hetarylalkyl, aryl, arylalkyl or C3-C 7 cycloalkyl radicals for R A 1 or R A 2 are understood independently of one another, for example, to mean the corresponding radicals described above for R G 1 .
  • the optionally substituted radicals CO-0-R A 14 , 0-R A 14 , SR A 14 , NR A 15 R A 16 , CO-NR A 15 RA 16 or S0 2 NR A 15 R A 16 stand for RA 1 or R A 2, for example from the groups CO-O, O, S, N, CO-N or S0 2 -N and the radicals R A 14 , R A 15 or R A 16 described in more detail below.
  • both radicals R A 1 and R A 2 together can contain a fused, optionally substituted, 5- or 6-membered, unsaturated or aromatic carbocycle or heterocycle which can contain up to three heteroatoms selected from the group O, N, or S, form.
  • R A 13 and R A 13 * independently of one another denote hydrogen, CN,
  • Halogen such as fluorine, chlorine, bromine or iodine
  • a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl radical as described for example above for RQ 1 , preferably methyl or trifluoromethyl or
  • R A 13 and R A 13 * are the radicals hydrogen, F, Cl, a branched or unbranched, optionally substituted C ⁇ -C 6 -alkyl radical, optionally substituted aryl or Arylalkyl or a radical CO-0-R A 14 , 0-R A 14 , NR A 15 R A 16 , S0 2 -NR A 15 R A 1 6 or C0-NR A 15 R A 16 .
  • C ⁇ -C 6 alkyl, C 3 -C 7 cycloalkyl, alkylene cycloalkyl, alkylene C--C 4 alkoxy, C 2 -C 6 alkenyl or C 2 -C 6 -alkynyl radical for R A 14 in structural element A are understood, for example, to be the corresponding radicals described above for RQ 1 .
  • Optionally substituted aryl, arylalkyl, hetaryl or alkylhetaryl radicals for R A 14 in structural element A are understood to mean, for example, the corresponding radicals described above for RG 1 .
  • Preferred radicals for R A 14 are hydrogen, a branched or unbranched, optionally substituted C ⁇ -C ⁇ -alkyl radical and optionally substituted benzyl.
  • R A 15 or R A 16 are, for example, independently of one another corresponding radicals described above for R A 14 understood.
  • the branched or unbranched, optionally substituted CO-C ⁇ -C 6 -alkyl-, S0 2 -C ⁇ -C 6 -alkyl-, C00-C ⁇ -C 6 -alkyl-, CO-NH-C ⁇ -C 6 -alkyl-, COO-alkylene-aryl, CO-NH-alkylene-aryl, CO-NH-alkylene-hetaryl or S0 2 -alkylene-aryl radicals or the optionally substituted CO-aryl, S0 2 -aryl, CO-NH-aryl -, CO-NH-hetaryl or CO-hetaryl residues for R A 15 or R A 16 are composed, for example, of the corresponding groups -CO-, -S0 2 -, -CO-O-, -CO-NH- and the corresponding, described above branched or unbranched, optionally substituted C ⁇ -C 6 alkyl, hetarylalkyl or arylalky
  • a radical - (CH 2 ) ⁇ - (XA) J-RA 12 for R A 3 or R A 4 is understood independently of one another to be a radical which is composed of the corresponding radicals - (CH 2 ) n -, (X A ) J and R A 12 composed.
  • N 0, 1, 2 or 3 and j: 0 or 1.
  • X A represents a double bonded residue, selected from the group -CO-, -CO-NfRx 1 ) -, -N Rx -CO-, -N (R ⁇ i ) -CO-N Rx 1 *) -, - tRx - CO-O-, -O-, -S-, -S0 2 -, -S0 2 -N (R x 1 ) -, -S0 2 -0-, -CO-O-, -O-CO-, - O-CO-NfRx 1 ) -, - «(Rx 1 ) - or -N (R ⁇ i ) -S0 2 -.
  • R A 12 means hydrogen
  • R A 12 and R 1 or Rx 1 * together can form a saturated or unsaturated C 3 -C 4 heterocycle which may optionally contain up to two further heteroatoms selected from the group O, S or N.
  • N-pyrrolidinyl N- Piperidinyl, N-hexahydroazepinyl, N-morpholinyl or N-
  • Aryl, CO aryl, S0 2 aryl, hetaryl, CO hetaryl or S0 2 alkyl aryl radicals are used independently of one another for R x x and R ⁇ x * - for example the radicals described above for R L 14 and R L 14 *.
  • Preferred radicals for Rx 1 and Rx 1 * are independently hydrogen, methyl, cyclopropyl, allyl and propargyl.
  • R A 3 and R A 4 may also together form a 3 to 8-membered, saturated, unsaturated or aromatic N-heterocycle which may additionally contain two further, identical or different heteroatoms 0, N, or S, the cycle optionally being substituted or a further, optionally substituted, saturated, unsaturated or aromatic cycle may be fused onto this cycle,
  • R A 5 represents a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl, arylalkyl, C ⁇ -C 4 alkyl-C 3 -C 7 cycloalkyl or C 3 -C 7 cycloalkyl radical or an optionally substituted aryl, hetaryl, heterocycloalkyl or heterocycloalkenyl radical, as described for example above for RQ 4 , R G 5 and RQ 6 .
  • R A 6 and R A 6 * independently of one another denote hydrogen, a branched or unbranched, optionally substituted
  • C ⁇ -C 4 alkyl such as optionally substituted methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl or 1, 1-dimethylethyl,
  • -CO-0-C ⁇ -C 4 -alkyl or -CO-C ⁇ -C 4 -alkyl radical such as composed, for example, of the group -CO-O- or -CO- and the above-described C ⁇ -C-alkyl radicals,
  • -CO-O-alkylene-aryl or -CO-alkylene-aryl radical such as, for example, composed of the group -CO-O- or -CO- and the arylalkyl radicals described above,
  • both radicals R A 6 and R A 6 * in structural element I A 7 together can form an optionally substituted, saturated, unsaturated or aromatic heterocycle which additionally can form up to two further different or identical heteroatoms 0, N, S to form ring nitrogen.
  • R A 7 is hydrogen, -OH, -CN, -CONH 2 / a branched or unbranched, optionally substituted C ⁇ -C 4 alkyl radical, for example as described above for R A 6 , C ⁇ -C 4 alkoxy, arylalkyl or C 3 -C 7 cycloalkyl, for example as described above for R L 14 , a branched or unbranched, optionally substituted -0-CO-C ⁇ -C 4 alkyl radical, which is selected from the group -0-CO- and, for example, from the above-mentioned C ⁇ -C 4 alkyl radicals or an optionally substituted -O-alkylene-aryl, -O-CO-aryl, -O-CO-alkylene-aryl or -O-CO-allyl radical which is composed of the groups -O- or -O-CO- and composed, for example, of the corresponding radicals described above for R G 1 .
  • both radicals R A 6 and R A 7 together can form an optionally substituted, unsaturated or aromatic heterocycle which, in addition to the ring nitrogen, can contain up to two further different or identical heteroatoms O, N, S.
  • a branched or unbranched, optionally substituted C ⁇ -C-alkyl radical or an optionally substituted aryl or arylalkyl radical for R A 8 in structural element A are understood to mean, for example, the corresponding radicals described above for R A 15 , the radicals being CO-C ⁇ -C 4 -alkyl, S ⁇ 2 -C ⁇ -C 4 -alkyl, CO-0-C ⁇ -C -alkyl, CO-aryl, S0 2 -aryl, CO-O-aryl, CO-alkylene-aryl, S0 2 - Alkylene-aryl or CO-O-alkylene-aryl analogous to the other composite radicals from the group CO, S0 2 or COO and for example from the corresponding C ⁇ -C 4 alkyl, aryl or arylalkyl radicals described above for R A 15 composed and these radicals can optionally be substituted.
  • each of R A 9 or R A 10 is, for example, the corresponding, above radicals described for R A 14 , preferably methyl or trifluoromethyl.
  • both radicals R A 9 and R A 10 together in structural element I A 14 can have a 5 to 7-membered saturated, unsaturated or aromatic carbocycle or heterocycle which can contain up to three different or identical heteroatoms 0, N, S and, if appropriate is substituted with up to three identical or different radicals.
  • optionally substituted C ⁇ -C 6 alkyl radical or an optionally substituted aryl, arylalkyl, hetaryl, C 3 -C 7 cycloalkyl radical or a radical CO-0-R A 14 , 0-R A 14 , SR A 14 , NR A 15 R A 16 , S0 2 -NR A 15 R A 16 or CO- NR A 15 R A 16 are understood for RA 11, for example, the corresponding radicals described above for R A 9 .
  • both radicals R A 9 and R A 17 together can form a 5 to 7-membered saturated, unsaturated or aromatic heterocycle which, in addition to the ring nitrogen, can contain up to three different or identical heteroatoms O, N, S and optionally with up to three identical or different radicals are formed.
  • C ⁇ -C 8 -alkyl- Under a branched or unbranched, optionally substituted C ⁇ -C 8 -alkyl-, C 2 -C 6 -alkenyl-, C 2 -C 6 -alkynyl-, C--C 5 -alkylene-C ⁇ -C 4 -alkoxy- , mono- and bis-alkylaminoalkylene or acylaminoalkylene or an optionally substituted aryl, heterocycloalkyl, heterocycloalkenyl, hetaryl, C 3 -C 7 cycloalkyl, C ⁇ -C 4 -alkylene-C3-C 7 -cycloalkyl -, Arylalkyl-, C ⁇ -C 4 -alkylene- heterocycloalkyl, C ⁇ -C 4 -alkylene-heterocycloalkenyl or hetarylalkyl radical, or a radical -S0 2 -R G 4
  • Zi, z 2 'Z 3 ' Z 4 are independently nitrogen, CH, C-halogen, such as CF, C-Cl, C-Br or CI or a branched or unbranched, optionally substituted C-C ⁇ -C 4 alkyl radical extending r example, a C ⁇ -C described above for R a 6 4 alkyl radical composed or a branched or unbranched, optionally substituted C-C ⁇ -C 4 alkoxy from a carbon radical and from which a carbon residue and, for example, a C ⁇ -C 4 alkoxy residue described above for R A 7 .
  • C-halogen such as CF, C-Cl, C-Br or CI or a branched or unbranched
  • optionally substituted C-C ⁇ -C 4 alkyl radical extending r example, a C ⁇ -C described above for R a 6 4 alkyl radical composed or a branched or unbranched, optionally substituted C-C ⁇ -C 4 alkoxy from
  • Z 5 means oxygen, sulfur or a radical NR A 8 .
  • Preferred structural elements A are composed of at least one preferred radical of the radicals belonging to structural element A, while the remaining radicals are widely variable.
  • Particularly preferred structural elements A are composed of the preferred residues of structural element A.
  • the spacer structural element E is understood to mean a structural element which consists of a branched or unbranched, optionally substituted and heteroatom-containing aliphatic C 2 -C 3 -hydrocarbon radical and / or of a 4- to 20-membered, if appropriate substituted and containing heteroatoms, aliphatic or aromatic mono- or polycyclic hydrocarbon radical.
  • the spacer structural element E means a structural element of the formula I E
  • RE 1 , RE 2 independently of one another are hydrogen, a branched or unbranched, optionally substituted C ⁇ -C 6 -alkyl-, C ⁇ -C 6 -alkoxyalkyl-, C 2 -C 6 -alkenyl-, C 2 -C ⁇ 2 -alkynyl-, CO-C ⁇ -C 6 -alkyl-, CO-0-C ⁇ -C 6 -alkyl-, CO- NH-C ⁇ -C 6 -alkoxalkyl-, CO-NH-CC 6 -alkyl- or S0 2 -C ⁇ -C 6- alkyl radical or an optionally substituted hetaryl, arylalkyl, C 3 -C 7 cycloalkyl, CO-O-alkylene-aryl, CO-NH-alkylene-aryl, CO-alkylene-aryl, CO-aryl, CO-NH-aryl, S0 2 -aryl, CO-hetaryl, S0 2
  • RE 3 , RE, RE 5 , RE 6 , RE 7 , RE 8 , RE 9 , RE 10 independently of one another hydrogen, halogen, a hydroxyl group, a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl—, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl or alkylene-cycloalkyl radical, a radical - (CH 2 ) X - (Y E ) Z R E 11 , an optionally substituted C 3 -C 7 cycloalkyl, aryl -, Arylalkyl—, Hetaryl— or Hetarylalkylrest or independently of each other two residues R E 3 and R E 4 or R E 5 and R E 6 or R E 7 and R E 8 or R E 9 and R E 10 together a 3 to 7-membered, optionally substituted, saturated or unsaturated carbo- or heterocycle, which can contain up to three heteroatoms from
  • R y 2 ' R y 2 * independently of one another hydrogen, a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl, C 2 -C 8 alkynyl, C 2 -C 6 alkenyl, C0-C ⁇ -C 6 -alkyl-, CO-0-C ⁇ -C 6 -alkyl or S0 2 -C ⁇ -C 6 -alkyl radical or an optionally substituted hetaryl, hetarylalkyl, arylalkyl, C 3 -C 7 -cycloalky 1-, CO- O-alkylene aryl, CO alkylene aryl, CO aryl, SO 2 aryl, CO hetaryl or SO 2 alkylene aryl radical, R E 11 is hydrogen, a hydroxyl group, CN, halogen, a branched or unbranched, optionally substituted C ⁇ -C6-alkyl radical, an optionally substituted C 3 -C 7 cycl
  • R E 12 is hydrogen, a branched or unbranched, optionally substituted Cx-C ⁇ -alkyl, C 2 -C 6 alkenyl, C 2 -C 8 alkynyl, an optionally substituted C 3 -C 7 cycloalkyl, hetaryl -, Arylalkyl- or hetarylalkyl radical or a radical C0-R E 16 , C00R E 16 or S0 2 -R E 16 ,
  • RE 13 , RE 14 independently of one another are hydrogen, a hydroxyl group, a branched or unbranched, optionally substituted C ⁇ -C 6- alkyl—, C ⁇ -C4-alkoxy—, C 2 -C 6 -alkenyl—, C 2 -C 6 -alkynyl - or alkylene cycloalkyl or an optionally substituted C 3 -C 7 cycloalkyl, aryl, arylalkyl, hetaryl or hetarylalkyl radical
  • R E 15 is hydrogen, a branched or unbranched, optionally substituted C ⁇ -C6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or alkylene cycloalkyl radical or an optionally substituted C 3 -C 7 - Cycloalkyl, aryl, arylalkyl, hetaryl or hetarylalkyl radical,
  • R E 16 is hydrogen, a hydroxy group, a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or Cx-Cs-alkylene -C ⁇ -C 4 alkoxy, or an optionally substituted aryl, heterocycloalkyl, heterocycloalkenyl, hetaryl, C 3 -C cycloalkyl, C ⁇ -C4 alkylene-C 3 -C 7 cycloalkyl, arylalkyl -, C ⁇ -C4-alkylene-C 3 -C 7 heterocycloalkyl, C ⁇ -C 4 alkylene-C 3 -C 7 heterocycloalkenyl or hetarylalkyl radical and
  • Q E is an optionally substituted 4 to 11-membered mono- or polycyclic, aliphatic or aromatic hydrocarbon which can contain up to 6 double bonds and up to 6 identical or different heteroatoms selected from the group N, 0 or S, the ring carbons or Ring nitrogen may optionally be substituted,
  • U E in structural element E means oxygen, sulfur or NR E 2 , with sulfur or NR E 2 being preferred and NR E 2 being particularly preferred.
  • the coefficients h and i are independently 0 or 1.
  • the coefficient i is 1.
  • the branched or unbranched, optionally substituted radicals C0-C ⁇ -C 6 alkyl, C0-0-C ⁇ -C 6 alkyl, C0-NH-C ⁇ -C 6 alkoxalkyl, CO-NH- C ⁇ -C 6 alkyl or S ⁇ 2 -C ⁇ -c 6 alkyl radical or the optionally substituted radicals CO-O-alkylene-aryl, CO-NH-alkylene-aryl, CO- Alkylene-aryl, CO-aryl, CO-NH-aryl, S0 2 -aryl, CO-hetaryl, S0 2 -alkylene-aryl, S ⁇ 2 -hetaryl or S0 2 -alkylene-hetaryl are for R E X and R E 2 independently of one another, for example, from the corresponding groups CO, COO, CONH or SO 2 and the corresponding radicals mentioned above.
  • Preferred radicals for RE 1 or R E 2 are independently hydrogen, a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl, C ⁇ -C 6 alkoxy, C 2 -C 6 alkenyl, C 2 -C ⁇ 2 -alkynyl or arylalkyl radical, or an optionally substituted hetaryl or C 3 -C 7 cycloalkyl radical.
  • radicals for RE 1 or R E 2 are hydrogen, methyl, cyclopropyl, allyl or propargyl.
  • k2, k4 or k6 can be 0 or 1 and kl, k3, k5 or k7 can be 0, 1 or 2.
  • C 6 -C alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or alkylene cycloalkyl radical or an optionally substituted C 3 -C cycloalkyl radical Aryl, arylalkyl, hetaryl or hetarylalkyl radical are used for R E 3 , R E 4 , RE 5 , RE 6 , RE 7 , RE 8 , RE 9 or R E ! 0 independently of one another, for example, the corresponding radicals mentioned above for 1 understood.
  • two radicals R E 3 and R E 4 or R E 5 and R E 6 or R E 7 and R E 8 or R E 9 and R E 10 together can form a 3- to 7-membered, optionally substituted, saturated or unsaturated carbo- or heterocycle, which can contain up to three heteroatoms from the group O, N or S, form.
  • the radical - (CH 2 ) X - (Y E ) Z -RE 11 is composed of a C 0 -C 4 alkylene radical, optionally a binding element Y E selected from the group -CO-, -CO-N (R y 2 ) -, -N (R y 2 ) -C0-, -N (R y 2 ) -CO-N (R y 2 *) -, -N (R y 2 ) -CO-O-, -0-, -S-, -S0 2 -, -S0 2 -N (R y 2 ) -, -S0 2 -0-, -CO-O-, -O-CO -, -0-CO-N (R y 2 > -, -N (R y 2 ) - or -N (R y 2 ) -S0 2 -, preferably selected from the group -C0-N (R y 2 )
  • R y is 2 and R 2 * y are independently hydrogen, a branched or straight-chain ⁇ , optionally substituted C ⁇ -C 6 alkyl, C 2 -C 6 nyl- -Alke-, C 2 -C 8 alkynyl, CO -C ⁇ -C 6 alkyl, CO- ⁇ -C ⁇ -C 6 alkyl or S0 2 -C ⁇ -C 6 alkyl radical or an optionally substituted hetaryl, hetarylalkyl, arylalkyl, C 3 -C 7 cycloalkyl, CO -O-alkylene-aryl, CO-alkylene-aryl, CO-aryl, S0 2 -aryl, CO-hetaryl or S0 2 -alkylene-aryl radical, preferably independently of one another hydrogen, methyl, cyclopropyl, allyl, propargyl, and
  • Hydrogen a hydroxy group, CN, halogen, a branched or unbranched, optionally substituted C ⁇ -C 6 -alkyl radical, an optionally substituted C 3 -C 7 -cycloalkyl—, aryl—, heteroaryl or arylalkyl radical, one optionally with C ⁇ -C 4 - Alkyl or aryl substituted C 2 -C 6 alkynyl or C 2 C ⁇ alkenyl, an optionally substituted C ⁇ C ⁇ 2 bicycloalkyl, Cx-C ß alkylene-C ⁇ C ⁇ 2 bicycloalkyl, C 7 -C 20 —Tricycloalkyl- or C ⁇ -C-alkylene-C 7 —C 2 o —tricycloalkyl radical, or a 3- to 8-membered, saturated or unsaturated heterocycle substituted by up to three identical or different radicals, of up to three can contain different or identical heteroatoms O, N, S, where two radicals together
  • R E U and R y 2 or R y 2 * together can form a saturated or unsaturated C 3 -C 7 heterocycle which may optionally contain up to two further heteroatoms selected from the group 0, S or N.
  • the radicals R E U and R y 2 or R y 2 * together form a cyclic amine as a C3-C 7 heterocycle, in the event that the radicals are bonded to the same nitrogen atom, such as, for example, N-pyrrolidinyl, N-piperidinyl , N-hexahydroazepinyl, N-morpholinyl or N-piperazinyl, wherein bearing free ⁇ minprotonen at heterocycles, such as N-piperazinyl, the free ⁇ minprotonen by customary amine protecting groups, such as methyl, Ben ⁇ zyl, Boc (tert-butoxycarbonyl), Z (Benzyloxycarbonyl), tosyl, -S0 2 -C ⁇ -C 4 alkyl, -S0 2 -phenyl or -S0 2 -benzyl can be replaced.
  • nitrogen atom such as, for example, N-pyrrolidinyl, N-piperidinyl
  • R E 3 , R E 4 , R E 5 , R E 6 , R E 7 , R E 8, R E 9 or R E 10 are independently hydrogen, a branched or unbranched, optionally substituted Ci-C ⁇ - Alkyl radical, optionally substituted aryl or the radical - (CHzJ x -fYEJ z -RE 11 .
  • a radical of R E 3 and R E 4 or R E 5 and R E 6 or R E 7 and Rg 8 or R E 9 and R E 10 denotes hydrogen or methyl.
  • radicals R E 3 , R E 4 , R E 5 , R E 6 , R E 7 , R E 8 , R E 9 or R E 10 independently of one another are hydrogen or methyl.
  • R E 12 represents hydrogen, a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 8 alkynyl radical or an optionally substituted C 3 -C 7 cycloalkyl, Hetaryl, arylalkyl or hetarylalkyl radical, as described, for example, in each case above for RL 1 or a radical CO-R E 16 , COOR E 16 or S0 2 -R E 16 , preferably hydrogen, methyl, allyl, propargyl and cyclopropyl.
  • R E 13 , R E 14 or R E 15 are understood independently of one another, for example, the corresponding radicals described above for R L X.
  • a branched or unbranched, optionally substituted C ⁇ -C 4 alkoxy radical for R E 13 or R E 14 is understood independently of one another, for example, to be the C 1 -C 4 alkoxy radicals described above for R A 14 .
  • Preferred alkylene-cycloalkyl radicals for R E 13 , R E 14 or R E 15 independently of one another are, for example, the C ⁇ -C4-alkylene-C 3 -C 7 cycloalkyl radicals described above for R L 1 .
  • the ring carbons or ring nitrogen may optionally be substituted for Q E, preferably optionally substituted arylene, such as optionally substituted phenylene or naphthylene, optionally substituted hetarylene such as the radicals
  • the remnants can be installed in both orientations.
  • z 6 and Z 7 independently of one another represent CH or nitrogen.
  • Z 8 means oxygen, sulfur or NH
  • Z 9 means oxygen, sulfur or NR E 19 .
  • rl, r2, r3 and t are independently 0, 1, 2 or 3,
  • s and u are independently 0, 1 or 2.
  • Q E particularly preferably denotes optionally substituted phenylene, a radical
  • R E 17 and R E 18 independently of one another are hydrogen, -N0 2 / -NH 2 , -CN, -COOH, a hydroxyl group, halogen is a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl—, C ⁇ -C alkoxy -, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl or alkylene cycloalkyl or an optionally substituted C 3 -C 7 cycloalkyl, aryl, arylalkyl, hetaryl or hetarylalkyl radical, such as each described above.
  • R E 19 independently of one another is hydrogen, a branched or unbranched, optionally substituted C 6 -C 6 -alkyl-, C ⁇ -C 6 -alkoxyalkyl, C 3 -C 12 -alkynyl-, CO-C ⁇ -C 6 -alkyl- , CO- O-Cx-Ce-alkyl— or S0 2 -C ⁇ -C 6 -alkyl radical or an optionally substituted C 3 -C 7 -cycloalkyl-, aryl, arylalkyl-, CO-O-alkylene-aryl—, CO- Alkylene-aryl, CO-aryl, S0 2 -aryl, hetaryl, CO-hetaryl— or S0 2 -alkylene-aryl radical, preferably hydrogen or a branched or unbranched, optionally substituted C ⁇ -C 6 alkyl radical.
  • Preferred structural elements E are composed of at least one preferred radical of the radicals belonging to structural element E, while the remaining radicals are widely variable.
  • Particularly preferred structural elements E are composed of the preferred residues of structural element E.
  • Preferred structural elements B are composed either of the preferred structural element A, while E is widely variable, or of the preferred structural element E, while A is widely variable.
  • the compounds of the formula I and also the intermediates for their preparation can have one or more asymmetrically substituted carbon atoms.
  • the compounds can exist as pure enantiomers or pure diastereomers or as a mixture thereof.
  • the use of an enantiomerically pure compound as the active ingredient is preferred.
  • the compounds of formula I can also exist in other tautomeric forms.
  • the compounds of the formula I can also be in the form of physiologically tolerable salts.
  • the compounds of the formula I can also be present as prodrugs in a form in which the compounds of the formula I are released under physiological conditions.
  • group T in structural element L which partially contains groups which can be hydrolyzed to the free carboxylic acid group under physiological conditions.
  • Derivatized structural elements B or A are also suitable which release the structural element B or A under physiological conditions.
  • one of the three structural elements B, G or L has the preferred range, while the remaining structural elements are widely variable.
  • two of the three structural elements B, G or L each have the preferred range, while the remaining structural elements are widely variable.
  • Preferred compounds of the formula I have, for example, the preferred structural element L, while the structural elements B and G are widely variable.
  • F urther most preferred compounds have the preferred structural elements A, G and L, while the structural elements E are widely variable.
  • F urther most preferred compounds have the preferred structural elements A, E, G and L on.
  • the compounds of the formula I and the starting materials used for their preparation can generally be prepared by methods of organic chemistry known to the person skilled in the art, as described in standard works such as Houben-Weyl, "Methods of Organic Chemistry", Thieme-Verlag, Stuttgart, or March , described "Advanced Organic Chemistry", 4 th Edition, Wiley & Sons. Further production methods are also described in R.
  • a preferred method for the synthesis of 4-thioxo-3,4-dihydropyrimidine-2 (li ⁇ ) -ones is, for example, the addition of enamines to isothiocyanates with subsequent cyclization, as described by Goerdeler et al. in Chem. Ber. 1963, pp. 526-533, and Chem. Ber. 1965, pp. 1531-1542.
  • 4-Thioxo-3,4-dihydropyrimidin-2 (1H) -one can be particularly preferably according to that of Lamon in J. Heterocycl. Chem. 1968, 5, 837-844 represent the method described, which is based on the reaction of an enamine with alkoxy or aryloxycarbonyl isothiocyanate.
  • SGx stands for a protective group of the carboxylic acid function, or the rest SG ⁇ -OOC- for T, as described above.
  • SGx solid support.
  • Methods of solid phase synthesis are described in detail, for example, by Bunin in "The Combinatorial Index” (Academic Press, 1998).
  • U contains a further functional group or the side chain of an amino acid which contains a so-called side chain functionality, this is advantageously protected by suitable protective groups.
  • the 4-thioxo group is alkylated in compounds of the general formula II with the addition of a base by standard methods.
  • An alkali or alkaline earth metal hydride such as sodium hydride, potassium hydride or calcium hydride, a carbonate such as alkali metal carbonate, for example sodium or potassium carbonate, an alkali or alkaline earth metal hydroxide such as sodium or potassium hydroxide, an alcoholate such as sodium methoxide, Kaliumtert.butanolat, an organometallic compound such as butyl lithium or alkali ide such as lithium diisopropylamide, lithium, sodium or potassium bis (trimethylsilyl) amide, tertiary amines such as triethylamine, l, 8-diazabicyclo [5.4.0] undec- 7-ene or ethyl-diisopropylamine.
  • alkali carbonates such as Cs 2 CO 3 or tertiary amines such as
  • the 4-thioxo group is preferably converted into the corresponding thiocyanate by alkylation with cyanogen bromide, as described, for example, in Tetrahedron Letters 1991, 32 (22), 2505-2508 (Scheme II ) .
  • the thiocyanate of formula IVa may then be mineral or of the general formula AE (U E) h H (V) following art known methods, possibly with the addition of a base, convert alcohols to give the compounds of general formula VI with appropriate A ( Scheme II).
  • -E'- stands for the spacer structural element E without the binding member (U E ) -
  • the formula AEY (VII) can be used as alkylating agent directly Getting Connected a V are used, wherein the grouping Y is a conventional leaving group such as halogen such as chlorine, bromine, iodine or optionally halogen-, alkyl- or haloalkyl-substituted aryl- or a lkylsulfonyl such as toluenesulfonyl, trifluoromethanesulfonyl and methylsulfonyl, or another equivalent leaving group (scheme II).
  • halogen such as chlorine, bromine, iodine or optionally halogen-, alkyl- or haloalkyl-substituted aryl- or a lkylsulfonyl
  • a lkylsulfonyl such as toluenesulfonyl, trifluoromethanesulfonyl and methylsulfon
  • protective groups SG can all the expert from the Peptidsynt- hese are used well-known and common protection groups as well as in the standard works such as Bodanszky "The Practice of Peptide Synthesis", 2 nd Edition, Springer-Verlag, 1994, and Bodanszky “Principles of Peptide Synthesis ", Springer-Verlag 1984.
  • the protective groups in the compounds of the formula VI or the protective groups used in the preparation of the compounds V and VII are likewise cleaved according to conditions known to the person skilled in the art and, for example, from Greene and Wuts in "Protective Groups in Organic Synthesis", 2 nd e dition, Wiley & Sons, 1991.
  • Boc, Fmoc, benzyloxycarbonyl (Z), acetyl, trityl or Mtr are preferably used as amino protecting groups.
  • Suitable acid protecting groups such as are SG ⁇ f preferably C ⁇ -C 4 alkyl such as methyl, ethyl, tert-butyl or benzyl, or also T rityl, or else polymer-bound protective groups in the form of commercially available polystyrene resins such as 2-chlorotrityl chloride resin or Wang resin (Bachern, Novabiochem) are used.
  • the cleavage of acid-labile protective groups can be carried out using organic acids such as trifluoroacetic acid (TFA), trichloroacetic acid, perchloric acid, triflurethanol, sulfonic acids such as benzene or p-toluenesulfonic acid but also Anorga ⁇ African acids such as hydrochloric acid or sulfuric acid, carried out, where the acids are used in excess in general who ⁇ .
  • TFA trifluoroacetic acid
  • trichloroacetic acid perchloric acid
  • triflurethanol triflurethanol
  • sulfonic acids such as benzene or p-toluenesulfonic acid
  • Anorga ⁇ African acids such as hydrochloric acid or sulfuric acid
  • thiols such as e.g. Thioanisol or thiophenol may be advantageous.
  • the presence of an additional inert solvent is possible, but not always necessary.
  • Suitable inert solvents are preferably organic solvents, for example carboxylic acids such as acetic acid, ethers such as THF or dioxane, amides such as DMF or dimethylacetamide, halogenated hydrocarbons such as dichloromethane, alcohols such as methanol, isopropanol or water. Mixtures of the solvents mentioned are also suitable.
  • the reaction temperature for these reactions is between 10 ° C and 50 ° C, preferably in a range between 0 ° C and 30 ° C.
  • Base-labile protective groups such as Fmoc are cleaved by treatment with organic amines such as dimethylamine, diethylamine, morpholine, piperidine as 5-50% solutions in CH 2 C1 2 or DMF.
  • the reaction temperature for these reactions is between 10 ° C and 50 ° C, preferably in a range between 0 ° C and 30 ° C.
  • Acid protecting groups such as methyl or ethyl are preferably cleaved by basic hydrolysis in an inert solvent.
  • Alkali or alkaline earth metal hydroxides preferably NaOH, KOH or LiOH, are preferably used as bases.
  • All common inert solvents such as hydrocarbons such as hexane, heptane, petroleum ether, toluene, benzene or xylene, chlorinated hydrocarbons such as trichlorethylene, 1,2-dichloroethane, carbon tetrachloride, chloroform, dichloromethane, alcohols such as methanol, ethanol, isopropanol, n- Propanol, n-butanol or tert-butanol, ethers such as diethyl ether, methyl tert-butyl ether, diisopropyl ether, tetrahydrofuran, dioxane, glycol ethers such as
  • Protective groups which can be split off hydrogenolytically such as benzyloxycarbonyl (Z) or benzyl can e.g. by hydrogenolysis in the presence of a catalyst (e.g. a noble metal catalyst supported on activated carbon).
  • a catalyst e.g. a noble metal catalyst supported on activated carbon.
  • Suitable solvents are those specified above, in particular alcohols such as methanol or ethanol, amides such as DMF or dimethylacetamide, esters such as ethyl acetate.
  • the hydrogenolysis is usually carried out at a pressure of 1-200 bar and temperatures between 0 ° and 100 ° C; the addition of an acid such as Acetic acid or hydrochloric acid can be beneficial. 5-10% Pd on activated carbon is preferably used as the catalyst.
  • Type E blocks are generally constructed using methods known to those skilled in the art.
  • the building blocks used are either commercially available or accessible using methods known from the literature. The synthesis of some of these building blocks is described in the example section.
  • E8 isoxazoles , Oxazoles, thiazoles, pyrazoles, imidazoles and their benzo-fused representatives, and oxadiazoles, thiadiazoles and triazoles;
  • Vol. E9 pyridazines, pyrimidines, triazines, azepines and their benzo-fused representatives and purines).
  • Ureas or thioureas (AE-1 to AE-3) can be prepared by conventional methods of organic chemistry, eg via IMPLEMENTATION an isocyanate or a thioisocyanate with an A min, optionally in an inert solvent with heating (Houben-Weyl Volume VIII, 157ff.) (Scheme 3)
  • Scheme 4 shows an example of the representation of compounds of the type AE-4, as described, for example, by Blakemoore et al. in .Eur. J. Med. C hem. 1987 (22) 2, 91-100, or by Misra et al. in Bioorg. Med. Chem. Lett. 1994 4 (18), 2165-2170.
  • Guanidine derivatives of the general formulas AE-5 and AE-6 can be prepared using commercially available or easily accessible reagents, as described, for example, in Synlett 1990, 745, J. Org. Chem. 1992, 57, 2497, Bioorg. Med. Chem. 1996, 6, 1185-1208; Bioorgr. Med. Chem. 1998, 1185, or Synth. Comm. 1998, 28, 741-746.
  • AE-13 Compounds of the general formula AE-13 can be analogous to Froeyen et al., Phosphorits Sulfur Silicon Relat. Eggs. 1991, 63, 283-293, AE-14 analogous to Yoneda et al., Heterocycles 1998, 15 N'-1, Spec. Prepare Issue, 341-344 (Scheme 6). Corresponding connections can also be represented analogously to WO 97/36859:
  • the invention further relates to the use of the structural element of the formula Q
  • the invention further relates to medicaments containing the structural element of the formula I GL .
  • the invention further relates to pharmaceutical preparations containing, in addition to the usual pharmaceutical excipients, at least one compound of formula I.
  • the compounds according to the invention can be administered in the usual way orally or parenterally (subcutaneously, intravenously, intramuscularly, intrapertoneally). It can also be applied with vapors or sprays through the nasopharynx. Furthermore, the compounds according to the invention can be introduced by direct contact with the tissue concerned.
  • the dosage depends on the age, condition and weight of the patient and on the type of application. As a rule, the daily dose of active substance is between approximately 0.5 and 50 mg / kg body weight when administered orally and between approximately 0.1 and 10 mg / kg body weight when administered parenterally.
  • the new compounds can be used in the customary pharmaceutical application forms, solid or liquid, e.g. as tablets, film-coated tablets, capsules, powders, granules, dragees, suppositories, solutions, ointments, creams or sprays. These are manufactured in the usual way.
  • the active ingredients can be processed with the usual pharmaceutical auxiliaries such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, retardants, antioxidants and / or propellants (see H. Sucker et al .: Pharmaceuticals Technology, Thieme-Verlag, Stuttgart, 1991).
  • the administration forms obtained in this way normally contain the active ingredient in an amount of 0.1 to 90% by weight.
  • the invention further relates to the compounds of the formula I for use as medicaments and the use of the compounds of the formula I for the production of medicaments for the treatment of diseases.
  • the compounds of formula I can be used for the treatment of human and animal diseases.
  • the compounds of formula I bind to integrin receptors. They are therefore preferably suitable as integrin receptor ligands and for the production of medicaments for the treatment of diseases in which an integrin receptor is involved, in particular for the treatment of diseases in which the interaction between integrins and their natural ligands is misregulated, that is to say increased or decreased.
  • U nder be understood integrin agonists and antagonists.
  • U nder an excessive or reduced interaction is both an excessive or decreased expression of the natural ligand or and / or the integrin receptor and thus an excessive or reduced amount of natural ligand or and / or integrin receptor or an increased or decreased affinity of the natural ligand to the integrin receptor Understood.
  • the amount of incorrect regulation that leads to a pathophysiological situation depends on the individual organism and on the location and type of disease.
  • Preferred integrin receptors for which the compounds of the formula I according to the invention can be used, are the ⁇ sßx, ⁇ 4 ⁇ v, ⁇ v ßs- and ⁇ v ß 3 integrin receptors.
  • the compounds of the formula I particularly preferably bind to the ⁇ v ⁇ 3 integrin receptor and can therefore particularly preferably be used as ligands of the ⁇ v ⁇ 3 integrin receptor and for the treatment of diseases in which the interaction between ⁇ v ⁇ 3 integrin receptor and its natural Ligands that are elevated or decreased can be used.
  • the compounds of the formula I are preferably used for the treatment of the following diseases or for the preparation of medicaments for the treatment of the following diseases:
  • Cardiovascular diseases such as atherosclerosis, restenosis after vascular injury or stent implantation, and angioplasty (neoinimal formation, smooth muscle line migration and proliferation),
  • Angiogenesis-associated microangiopathies such as diabetic angiopathies or retinopathy or rheumatic arthritis
  • Cancer such as tumor metastasis or tumor growth (tumor-induced angiogenesis),
  • Osteoporosis bone resorption after chemotaxis and adhesion of osteoclasts to bone matrix
  • Hypertension psoriasis, hyperparathyroism, Paget's disease, malignant hypercalcemia, metastatic osteolytic lesions, inflammation, wound healing, heart failure, congestive heart failure CHF, as well as in
  • the compounds of formula I in combination ⁇ nation can be administered at least one other compound having, in order to achieve an enhanced therapeutic effect in a number of indications.
  • These further compounds can have the same or a different mode of action as the compounds of the formula I.
  • the pharmaceutical preparations can therefore contain at least one further compound, selected from one of the 10 groups below depending on the indication.
  • Inhibitors of platelet adhesion, activation or aggregation such as, for example, acetylsalicylic acid, lysine acetylsalicylic, pilacetym, dipyridamole, abciximab, thromboxane antagonists, fibrinogen antagonists, such as, for example, tirofiban, or inhibitor aggregation such as ADP or clopidogrel,
  • Anticoagulants that prevent thrombin activity or formation, such as inhibitors of Ila, Xa, Xla, iXa or Vlla,
  • Inhibitors of platelet activation or aggregation such as, for example, GPIIb / IIIa antagonists, thrombin or factor Xa
  • Fibrinolysis-modulating compounds such as strep tokinase, tPA, plasminogen activation stimulants, TAFI inhibitors, XIa inhibitors or PAI-1 antagonists,
  • Thrombin inhibitors inhibitors of factor Xa
  • Inhibitors of the coagulation pathway leading to thrombin formation such as heparin or low molecular weight heparins, inhibitors of platelet adhesion, activation or aggregation, such as GPIIb-IIIa antagonists or antagonists of platelet adhesion and activation mediated by vWF or GPIb,
  • Endothelin receptor antagonists Endothelin receptor antagonists, nitric oxide synthase inhibitors, CD44 antagonists, selectin antagonists, MCP-1 antagonists,
  • Inhibitors of signal transduction in proliferating cells antagonists of the cell response mediated by EGF, PDGF, VEGF or bFGF and antioxidants
  • Antagonists of those mediated by EGF, PDGF, VEGF or bFGF Antagonists of those mediated by EGF, PDGF, VEGF or bFGF
  • Group 7 cytostatic or antineoplastic compounds
  • hormone exchange therapy such as Estrogen or progesterone antagonists
  • Bone formation stimulants such as growth factor agonists, interleukin-6 antagonists and
  • VLA-4 or VCAM-1 antagonists are VLA-4 or VCAM-1 antagonists.
  • Interleukin-1, -5 or -8 antagonists and
  • a combined administration of at least one of the compounds of the formula 1 with at least one further compound is selected in each case from one of the groups described above and, where appropriate, pharmaceutical auxiliaries.
  • the combined administration can be carried out by means of a mixture containing at least one compound of the formula I, optionally pharmaceutical excipients and at least one further compound, depending on the indication, in each case selected from one of the above groups, but also spatially and / or temporally separated.
  • ⁇ he follows the administration of the components of tung Arzneistoffzuberei ⁇ , the compounds of formula 1 and the compounds selected from the aforementioned groups spatially and / or temporally separated.
  • the compounds of the formula I can be administered alone or in combination with at least one compound selected from group 4 locally to the affected sites. It can also be advantageous to coat the stents with these compounds.
  • the invention accordingly relates to the use of the pharmaceutical preparations mentioned above for the production of pharmaceuticals for the treatment of diseases.
  • the invention relates to the use of the aforementioned combined pharmaceutical preparations for the production of pharmaceuticals for the treatment of
  • N- [(9H-fluoren-9-ylmethoxy) carbonyl] -2- (2-naphthylmethyl) - ß-alanine-2-Cl-trityl resin thus obtained was twice with 20 min each with piperidine in DMF (50%) treated and then washed with DMF, CH 2 C1 2 , MeOH and CH 2 C1 2 . After drying in vacuo, 2.42 g of the deprotected resin were obtained (substitution l. Olmmol amino acid / g resin).
  • test system For the identification and evaluation of integrin- ⁇ v ⁇ 3 ligands, a test system was used which is based on a competition between the natural integrin ⁇ v ⁇ 3 ligand vitronectin and the test substance for binding to integrin- ⁇ v ⁇ 3 bound to solid phases .
  • Integrin- ⁇ v ß 3 Human placenta is solubilized with Nonidet and integrin- ⁇ v ß 3 affinity-purified on a GRGDSPK matrix (elution with EDTA). Contamination by integrin ⁇ ßrb ß 3 and human serum albumin as well as the detergent and EDTA are removed by anion exchange chromatography .
  • Assay buffer 50 mM Tris pH 7.5; 100 mM NaCl; 1 mM CaCl 2 ; 1 mM MgCl 2 ; 10 ⁇ M MnCl 2
  • Peroxidase substrate Mix 0.1 ml of TMB solution (42 mM TMB in DMSO) and 10 ml of substrate buffer (0.1 m Na acetate pH 4.9), then add 14.7 ⁇ l 3% H 2 0 2 .
  • the assay is based on a competition between the natural integrin- ⁇ n b ß 3 ligand fibrinogen and the test substance for binding to integrin- ⁇ nbß3-
  • biotinylated anti integrin- ⁇ lb ß 3 antibody (Dianova CBL 130 B); 1: 1000 in 0.1% BSA / PBS; 0.1 ml / well; 2 to 4 h / RT 3x wash as above
  • Streptavidin-peroxidase complex (B.M. 1089153) 1: 10000 in 0.1% BSA / PBS; 0.1 ml / well; 30 min / rt
  • Peroxidase substrate Mix 0.1 ml TMB solution (42 mM TMB in DMSO) and 10 ml substrate buffer (0.1 M Na acetate pH 4.9), then add 14.7 ⁇ l 3% H 2 0 2
  • IC 50 values concentration of the antagonist at which 50% of the ligand is displaced.
  • the selectivity of the substances can be determined by comparing the IC 50 values in the integrin ⁇ u b ß 3 and integrin ⁇ v b 3 assays.
  • the CAM (chorioallantoin membrane) assay serves as a generally recognized model for assessing the in vivo activity of integrin ⁇ v ⁇ 3 antagonists. It is based on the inhibition of angiogenesis and neovascularization of tumor tissue (Am. J. Pathol. 1975, 79, 597-618; Cancer Res. 1980, 40, 2300-2309; Nature 1987, 329, 630). The implementation is analogous to the state of the art. The growth of the chicken embryo blood vessels and the transplanted tumor tissue is easy to follow and evaluate.
  • Example 4 Rabbit Eye Assay
  • the inhibition of angiogenesis and neovascularization in the presence of integrin ⁇ v ⁇ 3 antagonists can be monitored and evaluated analogously to Example 3.
  • the model is generally recognized and is based on the growth of rabbit blood vessels from the edge into the cornea of the eye (Proc. Natl. Acad. Sei. USA. 1994, 91, 4082-4085; Science 1976, 193, 70-72).
  • the implementation is analogous to the state of the art.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés de pyrimidinone substitués, se liant à des récepteurs de l'intégrine, ainsi que leur production et leur utilisation.
EP02716798A 2001-02-23 2002-02-21 Derives de pyrimidinone substitues en tant que ligands de recepteurs de l'integrine Withdrawn EP1362046A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10108995 2001-02-23
DE10108995A DE10108995A1 (de) 2001-02-23 2001-02-23 Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
PCT/EP2002/001865 WO2002068410A1 (fr) 2001-02-23 2002-02-21 Derives de pyrimidinone substitues en tant que ligands de recepteurs de l'integrine

Publications (1)

Publication Number Publication Date
EP1362046A1 true EP1362046A1 (fr) 2003-11-19

Family

ID=7675393

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02716798A Withdrawn EP1362046A1 (fr) 2001-02-23 2002-02-21 Derives de pyrimidinone substitues en tant que ligands de recepteurs de l'integrine

Country Status (6)

Country Link
US (1) US20040259864A1 (fr)
EP (1) EP1362046A1 (fr)
JP (1) JP2004522800A (fr)
DE (1) DE10108995A1 (fr)
PE (1) PE20020954A1 (fr)
WO (1) WO2002068410A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030171368A1 (en) * 2002-02-06 2003-09-11 Werner Seitz Pyrimidinonesulfamoylureas`
JP4634303B2 (ja) * 2003-10-10 2011-02-16 興和株式会社 血管新生抑制薬
EA015252B1 (ru) 2005-05-10 2011-06-30 Интермьюн, Инк. Способ модуляции стресс-активированной протеинкиназной системы
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
US8642282B2 (en) * 2011-01-12 2014-02-04 Northwestern University Inhibitors of nitric oxide synthase for treatment of melanoma
CA2853024C (fr) 2011-11-11 2017-08-22 Pfizer Inc. 2-thiopyrimidinones
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
PE20180503A1 (es) 2015-05-05 2018-03-09 Pfizer 2-tiopirimidinonas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE170179T1 (de) * 1994-11-02 1998-09-15 Merck Patent Gmbh Adhäsionsrezeptor-antagonisten
DE19516483A1 (de) * 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
US6559144B2 (en) * 1997-02-13 2003-05-06 Merck Patent Gesellschaft Mit Bicyclic amino acids
US7125883B1 (en) * 1999-04-13 2006-10-24 Abbott Gmbh & Co. Kg Integrin receptor ligands
CA2393287A1 (fr) * 1999-12-17 2001-06-21 Samuel Paul Amdahl Appareil d'assemblage
US6769339B2 (en) * 2001-06-25 2004-08-03 General Binding Corporation Die set pin retainer

Also Published As

Publication number Publication date
PE20020954A1 (es) 2002-10-24
JP2004522800A (ja) 2004-07-29
WO2002068410A1 (fr) 2002-09-06
DE10108995A1 (de) 2002-09-05
US20040259864A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
ES2298820T3 (es) Derivados de arilo y heteroarilo trisustituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con los mismos.
US20070149508A1 (en) Six membered heteroaromatic inhibitors targeting resistant kinase mutations
AU2013332648B2 (en) Sodium channel blockers, preparation method thereof and use thereof
SG177740A1 (en) Substituted benzoimidazolesulfonamides and substituted indolesulfonamides as mglur4 potentiators
US20110319429A1 (en) Substituted 1,1,3,1-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP1289962A1 (fr) Ligands de l'integrine
EP1362046A1 (fr) Derives de pyrimidinone substitues en tant que ligands de recepteurs de l'integrine
EP1171435A2 (fr) Pyrimidine-2-one derives comme ligands de recepteurs d'integrine
EP1202988A2 (fr) Nouveaux antagonistes des recepteurs integrines
EP1286673B1 (fr) Ligands de recepteurs d'integrine
WO2002051810A2 (fr) Ligands des recepteurs des integrines
EP1173468A1 (fr) Antagonistes recepteurs d'integrine
US20030171368A1 (en) Pyrimidinonesulfamoylureas`
DE19962998A1 (de) Integrinrezeptorliganden
WO2002014320A2 (fr) Nouveaux derives de diareno-azepine substitues servant de ligands d'integrine
DE19948269A1 (de) Neue Integrinrezeptorantagonisten
DE19919218A1 (de) Neue Integrinrezeptorantagonisten
DE102004034380A1 (de) Verwendung von TRIAL und IkappaB-Kinase Inhibitoren in der Krebsbehandlung
ZA200108035B (en) Integrin receptor ligands.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030825

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SPRIESTERSBACH, RAINER

Inventor name: HORNBERGER, WILFRIED

Inventor name: SUBKOWSKI, THOMAS

Inventor name: GRAEF, CLAUDIA, ISABELLA

Inventor name: SEITZ, WERNER

Inventor name: LAUTERBACH, ARNULF

Inventor name: ZECHEL, JOHANN-CHRISTIAN

Inventor name: KLING, ANDREAS

Inventor name: GENESTE, HERV

17Q First examination report despatched

Effective date: 20051222

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070817